[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 132
1. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée qu'en est-il en pratique?
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • We found a higher frequency of laryngeal tumour in group 2 (31 vs 17; p =.03).
  • We observed more stage III and less stage IV in group 1.
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • The overall survival of the population (108 patients) was 81.5% at one year, 49.6% at 3 years and 35.3% at 5 years with a median survival of 3 years.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • If confirmed, cost effectiveness of such complication must be integrated in larynx preservation protocols.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Liu WS, Hsin CH, Chou YH, Liu JT, Wu MF, Tseng SW, Lee JK, Tseng HC, Wang TH, Su MC, Lee H: Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation. BMC Cancer; 2010;10:102
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
  • BACKGROUND: The objective of this retrospective study is to investigate laryngeal preservation and long-term treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined with chemotherapy.
  • METHODS: Twenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent concurrent chemoradiotherapy.
  • The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six patients and weekly cisplatin for 19 patients.
  • RESULTS: The median follow-up time for survivors was 53.0 months (range 36-82 months).
  • The initial complete response rate was 85.2%, with a laryngeal preservation rate of 63.0%.
  • The 5-year functional laryngeal, local-regional control, disease-free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively.
  • The most common greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal stricture (18.5%, 5 of 27 patients), respectively.
  • CONCLUSIONS: After long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-regional control survival rates.
  • However, the late effect of laryngeal stricture remains a problem, particularly for high risk group patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Larynx / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Radiotherapy, Intensity-Modulated / adverse effects. Radiotherapy, Intensity-Modulated / methods. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):195-205 [10656393.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21 [16168834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):65-71 [10758306.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Cancer. 2001 Apr 20;96(2):126-31 [11291096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Laryngoscope. 1977 Aug;87(8):1288-303 [881922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):357-63 [6423584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Cancer J. 2006 Nov-Dec;12(6):494-500 [17207319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):36-41 [17709149.001]
  • [Cites] Auris Nasus Larynx. 2007 Dec;34(4):499-504 [17604583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85 [18164838.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] Acta Otolaryngol. 2009 Mar;129(3):311-7 [18607975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):146-53 [19553034.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Head Neck. 2005 Jan;27(1):15-21 [15515158.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 May;262(5):374-8 [15906056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30 [10701741.001]
  • (PMID = 20298550.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3087314
  •  go-up   go-down


3. Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol; 2010 Jul 30;2:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.
  • BACKGROUND: To assess the results for local control (LC) and survival in patients with early-stage glottic cancer (GC) who were treated by radiotherapy (RT) with or without chemotherapy.
  • METHODS: Fifty-eight patients with T1-T2 squamous cell carcinoma of the glottis who were treated between 2001 and 2006 were analyzed retrospectively.
  • Of the 58 patients, eight developed recurrent disease at the primary site, and one had lymph node recurrences on the neck.
  • Only two patients died of laryngeal carcinoma, and one died of intercurrent disease.
  • CONCLUSIONS: The retrospective analysis showed a high rate of LC and larynx preservation in patients with T1-T2 GC by means of RT with or without chemotherapy.
  • There was, however, no statistical difference in LC rates for the two types of therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):21-6 [10656367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1104-9 [18950960.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4029-36 [11600604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):109-19 [11777628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):415-9 [11872287.001]
  • [Cites] Head Neck. 2002 Jul;24(7):637-42 [12112536.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):472-5 [12115532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):471-8 [12243824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8 [12527044.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):765-72 [12910521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):313-7 [3104243.001]
  • [Cites] Radiother Oncol. 1998 May;47(2):161-6 [9683364.001]
  • [Cites] Laryngoscope. 1998 Dec;108(12):1853-5 [9851503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1378-86 [16095847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1387-94 [16115737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82 [16169681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):995-1001 [16406396.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] Radiat Med. 2006 May;24(4):277-81 [16958401.001]
  • [Cites] Oncology. 2006;71(5-6):369-73 [17851262.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3497-500 [17972507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1389-94 [17869013.001]
  • [Cites] Auris Nasus Larynx. 2008 Jun;35(2):213-9 [17996416.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35 [11020569.001]
  • (PMID = 20673360.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2919535
  •  go-up   go-down


Advertisement
4. Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N: [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study]. Acta Otorrinolaringol Esp; 2003 Dec;54(10):697-703
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
  • [Transliterated title] Quimioterapia de inducción con vinorelbine, cisplatino y UFT en carcinomas avanzados faringo-laríngeos: resultados de un estudio fase II.
  • OBJECTIVE: To evaluate the results of an induction chemotherapy protocol with Vinorelbine, UFT and Cisplatin (UFTVP).
  • METHODS: 93 patients with laryngo-pharyngeal squamous cell carcinoma in stage III or IV were prospectively entered into a protocol to receive four cycles of UFTVP.
  • Responders followed definitive radiation therapy.
  • RESULTS: Following chemotherapy nodal response (complete in 28% and partial in 33%) was less than that the primary site (complete in 60% and partial in 30%), p = 0.002.
  • With a median follow-up of 62 months, the Kaplan-Meier 5-year survival was 45%.
  • Successful larynx preservation was achieved in 50% of patients with laryngeal cancer and in 29% of patients with hypopharyngeal cancer.
  • CONCLUSIONS: UFTVP is an active regime of chemotherapy in advanced squamous cell carcinoma of the pharynx and larynx.
  • Results differ according to the localization, having significantly better rates of survival and organ preservation in the laryngeal cancers that in those of the pharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngectomy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Prospective Studies. Remission Induction. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15164709.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; 1-UFT protocol
  •  go-up   go-down


5. Nagahashi T, Fukuda S, Homma A, Yagi K, Furuta Y, Inuyama Y: Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma. Auris Nasus Larynx; 2001 May;28 Suppl:S95-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma.
  • OBJECTIVE: To evaluate the efficacy and safety of concurrent carboplatin (CBDCA) and radiotherapy for laryngeal carcinoma. we investigated survival rates and laryngeal preservation rates in patients with this treatment modality and those with radiation therapy only.
  • METHODS: We underwent chemotherapy with CBDCA and conventional radiotherapy concurrently to 17 patients with untreated stage II (T2NOM0) supraglottic squamous cell carcinoma since November 1990.
  • CBDCA (100 mg/m2) was administered intravenously once a week concurrently with radiotherapy (2.5 Gy/fr, 4 times a week).
  • At the dose of 40 Gy, the results were evaluated, and some of the patients underwent planned surgery and others continued the radiotherapy up to 65 Gy.
  • Actual laryngeal preservation rate was 76.0%.
  • Compared with 14 cases of historical controls, which were treated by radiation therapy alone between 1988 and 1990, the cases with concurrent radiotherapy and chemotherapy had statistically significant advantage in overall successful laryngeal preservation rate (P < 0.05), whereas the two groups were not significantly different in the overall 5-year survival rate.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11683352.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Kohno N: The role of chemotherapy for advanced oro and hypopharyngeal cancer. Auris Nasus Larynx; 2004 Jun;31(2):113-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy for advanced oro and hypopharyngeal cancer.
  • Although important progress continuous to be made in the treatment of oro and hypopharyngeal cancer, the 5-year survival rate for all this disease has remained at less than 30% for the past 30 years.
  • In the early 1980s, chemotherapy was introduced with high expectation of reducing in the incidence of distant metastases and increasing the possibility of local control.
  • This article explores the use of chemotherapy in the treatment of advanced pharyngeal cancer.
  • Thus, the efficacy of chemotherapy are reviewed and treatment options for advanced pharyngeal cancer are made.
  • When advanced carcinoma is still localized, function-preserving surgery is performed.
  • In these cases, the possibility of instituting adjuvant chemotherapy with an active treatment regimen may be taken into account depending on the condition of the patient and the tumor.
  • Patients with surgically resectable tumors are given 1-2 cycles of induction chemotherapy.
  • Cases who respond to the induction chemotherapy are subsequently given concurrent chemoradiotherapy.
  • The cases who do not respond to the induction chemotherapy are treated with radical surgery.
  • Patients with unresectable carcinoma are given concurrent chemoradiotherapy because local treatment should be performed in such patients as early as possible.
  • In principle, concurrent regimens should be supplemented with adjuvant chemotherapy in all cases.
  • This is particularly required for those with advanced N-stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15121218.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


7. Lam P, Yuen AP, Ho CM, Ho WK, Wei WI: Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. Eur J Surg Oncol; 2001 Dec;27(8):750-3
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma.
  • AIMS: A prospective randomized study was conducted to evaluate the benefit of adjuvant levamisole/UFT (futraful and uracil) chemotherapy in head and neck squamous cell carcinoma.
  • METHODS: Sixty-five patients with stage III and IV squamous cell carcinomas of oral cavity, oropharynx, hypopharynx and larynx with no distant metastasis were randomized for the chemotherapy study.
  • Thirty-one patients were randomized for chemotherapy and two of them were subsequently excluded.
  • In this study, a total of 29 patients on levamisole/UFT therapy and 34 patients on the control group were analysed.
  • RESULTS: The rates of distant metastasis were 10% for chemotherapy group and 32% for control group (P=0.06).
  • The 5-year disease-free actuarial survival rates for patients with and without adjuvant chemotherapy were 57% and 39% respectively (P=0.207).
  • CONCLUSIONS: A trend of better distant control in head and neck cancer patients with post-operative adjuvant oral chemotherapy was observed.
  • It may be of value to conduct a large-scale multi-centre prospective randomized study to verify the efficacy of levamisole and UFT as post-operative adjuvant chemotherapy for the control of distant metastasis in high-risk population.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Levamisole / pharmacology. Uracil / pharmacology
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Radiotherapy, Adjuvant. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11735172.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 2880D3468G / Levamisole; 56HH86ZVCT / Uracil
  •  go-up   go-down


8. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB, EORTC Head and Neck Cancer Cooperative Group, EORTC Radiation Oncology Group: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst; 2009 Feb 04;101(3):142-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
  • BACKGROUND: Both induction chemotherapy followed by irradiation and concurrent chemotherapy and radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx or hypopharynx cancer.
  • We report results of the randomized phase 3 trial 24954 from the European Organization for Research and Treatment of Cancer.
  • METHODS: Patients with resectable advanced squamous cell carcinoma of the larynx (tumor stage T3-T4) or hypopharynx (T2-T4), with regional lymph nodes in the neck staged as N0-N2 and with no metastasis, were randomly assigned to treatment in the sequential (or control) or the alternating (or experimental) arm.
  • In the sequential arm, patients with a 50% or more reduction in primary tumor size after two cycles of cisplatin and 5-fluorouracil received another two cycles, followed by radiotherapy (70 Gy total).
  • In the alternating arm, a total of four cycles of cisplatin and 5-fluorouracil (in weeks 1, 4, 7, and 10) were alternated with radiotherapy with 20 Gy during the three 2-week intervals between chemotherapy cycles (60 Gy total).
  • The Kaplan-Meier method was used to obtain time-to-event data.
  • RESULTS: The 450 patients were randomly assigned to treatment (224 to the sequential arm and 226 to the alternating arm).
  • Survival with a functional larynx was similar in sequential and alternating arms (hazard ratio of death and/or event = 0.85, 95% confidence interval = 0.68 to 1.06), as were median overall survival (4.4 and 5.1 years, respectively) and median progression-free interval (3.0 and 3.1 years, respectively).
  • CONCLUSIONS: Larynx preservation, progression-free interval, and overall survival were similar in both arms, as were acute and late toxic effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant / methods. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Europe. Female. Fibrosis / etiology. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Laryngeal Edema / etiology. Male. Middle Aged. Mucositis / etiology. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Recovery of Function. Remission Induction. Research Design. Salvage Therapy / methods. Treatment Failure. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):811-4 [6204738.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1115-21 [1302472.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Oral Oncol. 1998 May;34(3):224-8 [9692058.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Oncologist. 2006 Feb;11(2):146-51 [16476835.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Feb 4;101(3):129-31 [19176460.001]
  • (PMID = 19176454.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002839
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-25; United States / NCI NIH HHS / CA / 5U10 CA11488-37
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2724854
  • [Investigator] de Montreuil B; Bensadoun RJ; Buter J; Coche-Dequeant B; Degardin M; Dehesdin D; Duvillard C; Kutem A; Langendiijk JA; Rame JP; Truc G; van den Weynaert D
  •  go-up   go-down


9. Mantz CA, Vokes EE, Kies MS, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ: Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol; 2001 Mar;12(3):343-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer.
  • PURPOSE: To determine overall survival, progression-free survival, rate of voice preservation, and patterns of failure in locoregionally advanced laryngeal cancer treated with induction chemotherapy with or without surgery followed by concomitant chemoradiation.
  • BACKGROUND: Locoregionally advanced laryngeal cancer has been conventionally treated with either surgery and adjuvant radiotherapy or radiotherapy alone, and clinical and functional outcomes have been poor.
  • Chemoradiotherapy has been demonstrated to improve functional outcome and disease control over conventional treatment in recent randomized head and neck trials.
  • Induction treatment consisted of three cycles of cisplatin, 5-fluorouracil (5-FU), leucovorin, and interferon-alpha 2b (PFL-IFN) followed by surgery for residual disease.
  • Surgical intent was to spare the larynx when possible.
  • RESULTS: A subset of thirty-two laryngeal cancer patients with predominantly stage IV disease comprises the study group for this report.
  • Clinical CR was observed in 59% of patients following induction therapy.
  • Only two total laryngectomies were performed during the course of treatment and follow-up.
  • Treatment-related toxicity accounted for two deaths.
  • CONCLUSIONS: The addition of concomitant chemoradiotherapy to induction chemotherapy for locoregionally advanced laryngeal cancer appears to increase locoregional control and survival rates.

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332146.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A: Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2007 Apr 1;67(5):1342-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
  • PURPOSE: To investigate the tumor control rates in locally advanced head-and-neck cancer using accelerated hypofractionated radiotherapy with chemotherapy.
  • METHODS AND MATERIALS: The data from patients with squamous cell cancer of the larynx, oropharynx, oral cavity, and hypopharynx (International Union Against Cancer Stage II-IV), who received accelerated hypofractionated radiotherapy with chemotherapy between January 1, 1998, and April 1, 2005, were retrospectively analyzed.
  • Two different chemotherapy schedules were used, carboplatin and methotrexate, both single agents administered on an outpatient basis.
  • When excluding patients with Stage II oral cavity, larynx, and hypopharynx tumors, 68 patients remained.
  • CONCLUSION: Accelerated hypofractionated radiotherapy and synchronous chemotherapy can achieve high tumor control rates while being resource sparing and should be the subject of prospective evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy / adverse effects. Dose Fractionation. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241752.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Yokoyama J: [Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer]. Gan To Kagaku Ryoho; 2002 Feb;29(2):169-75
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer].
  • Patients with head and neck squamous cell cancers (HNSC) of stage III and IV have a poor outcome, often losing important functions such as swallowing and speech despite combined surgery and radiotherapy.
  • Two-thirds of such patients die of local recurrence and disseminated metastasis in spite of salvage therapy.
  • Conventional adjuvant chemotherapy is often difficult for HNSC patients, since many of them suffer from associated chronic oral, respiratory and gastrointestinal diseases due to tobacco and alcohol in addition to having poor nutritional and oral hygienic conditions.
  • Ninety-seven patients with advanced head and neck cancers were treated by superselective intra-arterial chemotherapy using CDDP and sodium thiosulfate (STS) from 1995 to 2000.
  • The complete and partial response rates were 72% and 25%, respectively, with 100% preservation of the larynx and 90% preservation of the eyeball in all involved cases.
  • We could suppress mucositis of normal tissue and chemotoxicities leading to conditions such as renal and hematological dysfunction.
  • Though our method currently has disadvantages such as the risk of cerebral infarction, the fact that chemotherapy must always be done under fluoroscopy, and the occurrence of distant metastasis, there are good prospects for the future and we are now working toward solving the present problems.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Antidotes / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial / methods. Male. Middle Aged. Prospective Studies. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865620.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antidotes; 0 / Antineoplastic Agents; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 24
  •  go-up   go-down


12. Karasawa K, Umezawa T, Hanyu N, Kawamura H, Kiguchi Y, Mitsuhashi T, Niibe Y: Hyperfractionated radiation therapy for the treatment of squamous cell carcinoma of the head and neck. J Clin Oncol; 2004 Jul 15;22(14_suppl):5554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiation therapy for the treatment of squamous cell carcinoma of the head and neck.
  • : 5554 Background: Altered fractionation radiation therapy has been thought to improve the local control and survival of the patients with head and neck cancer.
  • Since 1996, we have been conducting a clinical trial of hyperfractionated radiation therapy (HFRT) for the treatment of squamous cell carcinoma of the head and neck (SCCHN).
  • Primary site: Larynx 34 cases, hypopharynx 27 cases, oropharynx 17 cases, oral cavity 5 cases, nasopharynx 4 cases, and maxillary sinus 2 cases.
  • Stage I/II/III/IV(M0) = 11/32/15/31.
  • Chemotherapy was combined in 22 cases.
  • OS and LC of stage I-II and III-IV were, 82.7%, 95.2%, and 54.5%, 53.5%, respectively.
  • As for larynx, OS and LC of overall, stage I-II, and stage III-IV were, 91.2%, 84.2%, 100%, 93.8%, and 50% (2y), 67% (1y), respectively.
  • As for oropharynx, OS and LC of overall, stage I-II, and stage III-IV were, 71.1%, 83.9%, 100% (2y), 100% (2y), and 73.8%, 80%, respectively.
  • As for hypopharynx, OS and LC of overall, stage I-II, and stage III-IV were, 49.9%, 65.3%, 53.6%, 100%, and 48.2%, 42.9%, respectively.
  • Disease-specific survival of stage I-II hypopharyngeal cancer was 100%.
  • CONCLUSIONS: HFRT for SCCHN was promising not only for stage III and IV(advanced) cases but also for stage I and II (early) cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Castro G, Snitcovsky IM, Gebrim EM, Diz MD, Nadalin W, Federico MH: Patients (pts) with stage IV, non-metastatic advanced head and neck squamous cell carcinoma (HNSCC) submitted to concurrent chemoradiotherapy (CCR) present with manageable toxicity. J Clin Oncol; 2004 Jul 15;22(14_suppl):8228

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients (pts) with stage IV, non-metastatic advanced head and neck squamous cell carcinoma (HNSCC) submitted to concurrent chemoradiotherapy (CCR) present with manageable toxicity.
  • METHODS: In this phase IV trial, previously untreated pts with locoregionally advanced, unresectable, HNSCC received 70 Gy, 200 cGy/d concurrent with cisplatin 100 mg/m<sup>2</sup> on days 1, 22 and 43.
  • Eligibility criteria included a histological proof of SCC, from oral cavity, oropharynx, hypopharynx, larynx or paranasal sinus; stage III/IV, M0 (AJCC, 2002); age 18-70 yrs; ECOG-PS 0-2; adequate organ function; measurable disease; assigned informed consent.
  • Pain (rate 0-10) and nutritional status were evaluated before and after treatment.
  • RESULTS: To date, 18 pts entered the trial, median age 54.5 yrs (37-68); 15 male; 16 PS1 and 1 PS2; 15 pts were able to eat orally; median body-mass index 19.7 kg/m<sup>2</sup> (13.8-27.3); primary site: oropharynx (10 pts), oral cavity (6), larynx (2); TNM: T3N1 (1 pt), T3N3 (1), T4N1 (5), T4N2 (5), T4N3 (6).
  • 11 pts completed radiation therapy (median time 64 d); median number of chemotherapy cycles: 2.
  • 9 pts required feeding tubes and red cell transfusion was done in 8 pts in order to maintain Hb level above 10 g/dL.
  • Pain score decreased by 3±3 after treatment (95%CI 1-5, p=0.007; paired t-test).
  • CCR is a feasible treatment strategy in this group of pts of locoregionally advanced HNSCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Mercke C, Wickart-Johansson G, Sjödin H, Adell G, Nyman J, Haugen H: Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer.
  • : 6040 Background: Concomitant chemoradiotherapy (CT/RT) is the standard treatment for locally advanced head and neck squamous cell carcinoma.
  • METHODS: Patients (pts) had previously untreated stage III/IV M0,WHO 0-1, unresectable squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx and were scheduled for 2 cycles of TPF (docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1 and 5-FU 1,000 mg/m2 96 hours CI) every 3 weeks followed by RT (68 Gy/4.5 weeks) with E given one week before (400 mg/m2) and weekly during RT (250 mg/m2).
  • A brachytherapy boost of 8 Gy was given to pts with oral cavity or oropharyngeal tumours.
  • Toxicity (CTC 3.0) and quality of life (EORTC QLQ 30) was registered during and after treatment.
  • RESULTS: From 070401 to 081115 68 pts were enrolled, 56 had stage IV disease (T4, n = 14, N3, n = 9).
  • Median age 57, 60 males, 3 oral cavity, 44 oropharynx, 10 larynx, and 11 hypopharynx.
  • 30 pts were followed beyond 6 weeks and evaluated for response and early toxicity: stage IV disease 24 (T4, n = 6, N3, n = 3), median age 60, 25 males, 18 oropharynx, 5 larynx, and 7 hypopharynx.
  • Dermatitis in the irradiated neck, at least with the present accelerated fractionation, is troublesome to some patients but does not interrupt treatment and heals rapidly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Levine MA, Saunders JR, Zinreich E, Kunar D, Price J, Hirata RM, Williams M: Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital. J Clin Oncol; 2004 Jul 15;22(14_suppl):5558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation therapy for advanced head and neck squamous cell carcinoma (HNSCC) in a community hospital.
  • : 5558 Background: Concurrent chemotherapy and radiation therapy have made organ preservation feasible in patients with advanced head and neck squamous cell carcinoma.
  • This study evaluates the use of chemotherapy with hyperfractionated radiation therapy in a community hospital and the importance of elective lymph node dissection for N2 and N3 patients.
  • METHODS: Forty-six patients with HNSCC stage III and IV (42/46 male, 35/46 oropharynx, 4 hypopharynx, 7 larynx, 25 N0-1, 21 N2-3) were treated.
  • Hyperfractionated radiation therapy was administered twice daily with an interval of at least six hours and a total dose of 7000cGy to the primary site and 5-6000cGy to the adjacent lymph node bearing areas.
  • Chemotherapy was administered during weeks 1 and 6 of radiation therapy and consisted of cis-platin 12mg/M2 IVPB days 1-5 and 5-fluorouracil 600mg/M2 continuous IV infusion over 20 hours days 1-5.
  • Two pts died in remission from intercurrent illnesses more than 11 months after completion of therapy.
  • TOXICITY: short term, all pts developed confluent mucositis but hospitalization for dehydration or infection was rare; long term, mouth dryness was common but manageable and most pts were PEG independent within three months of completion of therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Bardet E, Tuchais C, Calais G, Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC): Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol; 2009 May 20;27(15_suppl):6010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study.
  • : 6010 Background: Induction chemotherapy (ICT) followed by irradiation (RT) and concurrent chemoradiotherapy (CRT) are validated options for LP.
  • METHODS: Previously untreated patients (pts) with larynx or hypopharynx squamous cell carcinoma and candidates for a total laryngectomy were eligible for this randomized phase II study.
  • In case of response ≥ 50 % pts were randomized to receive either in arm A: RT (70 Gy) with cisplatin (100 mg/m<sup>2</sup> on days 1, 22 and 43 of RT) or in arm B: Cetuximab (400 mg/m<sup>2</sup> loading dose before RT and 250 mg/m<sup>2</sup> on the first day of the 7 weeks of RT.
  • Primary endpoint was LP 3 months after treatment, secondary endpoints were larynx function preservation at 18 months, quality of function and tolerance to treatment.
  • RESULTS: From March 2006 to April 2008 (end of accrual), 153 pts with stage III-IV larynx/hypopharynx cancer were enrolled in the study and could start ICT.
  • 3 months after treatment there was no significant difference in LP (93% in arm A and 96% in arm B).
  • In arm A 50% of pts had cisplatin-related toxicity (definitive in 52% the cases) while in arm B 26 % of patients had cetuximab-related toxicity (definitive in only 1 case).
  • There was no CRT treatment-related death.
  • ICT followed by RT with concurrent cetuximab appeared better tolerated than with concurrent cisplatin with the same LP rate 3 months after treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Pernas S, Leon X, Lopez-Pousa A, Quer M, Orus C, Guardeño R, Nadal R, Macarulla T, Gallego O, Lopez-Lopez J: Distant metastases in squamous-cell head and neck carcinoma (SHNC) patients who achieved loco-regional control (LRC). J Clin Oncol; 2004 Jul 15;22(14_suppl):5519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastases in squamous-cell head and neck carcinoma (SHNC) patients who achieved loco-regional control (LRC).
  • : 5519 Background: One of the reasons for failure in patients with SHNC who achieve loco-regional control with treatment is the appearance of distant metastases.
  • Patients with oral cavity, pharynx or larynx carcinoma who achieved loco-regional control were analyzed to evaluate the frequency of distant metastases and the influence of different variables in their appearance.
  • In the univariate study, the only variables that influenced the appearance of distant metastases in LRC pts were tumor site, T-stage, N-stage and histological differentiation.
  • On the multivariate analysis variables that increased the risk of distant metastases in LRC pts were N-stage (N0 vs N+), T-stage (T1 vs T>1), and the tumor location in the hypopharynx and the supraglottis.
  • Eighty % of the M1 appeared within the 2 years and no M1 patients were diagnosed after 4 years of the primary diagnosis (median time from diagnosis to M1=14 months).
  • In the group of 557 patients with locally advanced tumors who started treatment with chemotherapy the probability of M1 was 2.2% for CR (137 pts), 10.3% for PR (233 pts) and 19.7% for non-responder (137 pts) pts (p<.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Billan S, Abdah-Bortnyak R, Mezid F, Bernstein Z, Gez E, Nasrallah H, Kuten A: Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil before concurrent chemoradiotherapy or concurrent cetuximab-radiotherapy in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol; 2009 May 20;27(15_suppl):e17045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil before concurrent chemoradiotherapy or concurrent cetuximab-radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
  • : e17045 Background: Encouraging results have recently been reported in patients with locally advanced squamous cell carcinoma of the head and neck.
  • METHODS: Induction chemotherapy consisted of TPF (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2), 5-fluorouracil 750 mg/m(2)/d continuous infusion for 96 h) every three weeks, followed by CHT-RT regimen (radiotherapy 70 Gy total dose fractionated at 2Gy per day, 5 days a week concurrently with weekly cisplatin 40 mg/m(2) or cetuximab with loading dose of 400 one week before starting radiotherapy and 250 weekly during the radiotherapy) 4-7 weeks later.
  • Percutaneus endoscopic gastrectomy inserted before the combined treatment.
  • RESULTS: Between march 2007 and november 2008, 29 previously untreated patients (19 male and 4 female) with stage III-IV squamous cell carcinoma of the oral cavity, larynx, oropharynx, or hypopharynx were included to the study.
  • The stage distribution was as follows: stage II, 1 patient; stage III, 14 patients; and stage IV, 14 patients.
  • 16 patients had a performance status of 0 and 11 had a performance status of 1.
  • The combined treatment was interrupted only in 4 patients for one week.
  • Three cycles of TPF followed by combined treatment are feasible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961767.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Guadagnolo BA, Tishler RB, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Haddad RI: Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol; 2004 Jul 15;22(14_suppl):5600

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL).
  • : 5600 Background: We reviewed the charts of patients with laryngeal cancer treated with IC and definitive RT or CRT to determine the rates of overall organ preservation and function.
  • METHODS: Between September 1995 and December 2001, 29 patients with stage III (45%) and IV (55%) SCCL, were treated with IC and definitive RT or CRT on one of seven consecutive trials.
  • All received 3 cycles of IC with a platinum-based regimen.
  • Relapse occurred in12 (41%) patients, and 6 underwent salvage laryngectomy (5 Stage III, 1 Stage IV).
  • Of the entire cohort, 59% (17/29) are alive at last follow-up with an anatomically intact larynx, and 48% (14/29) are alive with a functional larynx.
  • Median time with G-tube was 12 months (range, 1-50 months), and 15/23 (65%) had g-tube for 6 months or longer.
  • 23 of all 29 patients (79%) retained an anatomically intact larynx, but 30% (7/23) did not resume their pre-treatment swallowing mechanics and airway protection.
  • The 7/29 patients (26%) who retained a non-functional larynx required permanent g-tube or were unable to return to pretreatment oral intake capability.
  • Nine of 13 with T4 SCCL (69%) compared to 7 of 16 (44%) T3 SCCL retained a functional larynx.
  • CONCLUSIONS: The rate of larynx preservation is high, but toxicity remains significant with combined modality therapy.
  • Advanced stage was not an indicator of poor outcome.
  • Half of all patients were alive, able to retain their larynx, and return to pretreatment function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015295.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fallai C, Bolner A, Signor M, Gava A, Franchin G, Ponticelli P, Taino R, Rossi F, Ardizzoia A, Oggionni M, Crispino S, Olmi P: Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori; 2006 Jan-Feb;92(1):41-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx.
  • AIMS AND BACKGROUND: To compare conventional fractionation (CF) radiation therapy (RT), arm A, versus a split-course accelerated hyperfractionated schedule (S-AHF), arm B, versus CFRT plus concomitant chemotherapy (CT), arm C, in terms of five-year survival and toxicity for squamous cell tumors of the oropharynx.
  • METHODS AND STUDY DESIGN: Between January 1993 and June 1998, 192 previously untreated patients with stage III and IV oropharyngeal carcinoma (excluding T1N1 and T2N1) were enrolled in a multicenter randomized phase III trial (ORO 93-01).
  • In arms A and C, 66 to 70 Gy in 33 to 35 fractions was administered five days a week for six and a half to seven weeks.
  • In arm B, the dose delivered was 64 to 67.2 Gy in two fractions of 1.6 Gy every day, five days a week, with a planned two-week split at 38.4 Gy.
  • In arm C the CT regimen consisted of three cycles of carboplatin and 5-fluorouracil (CBDCA 75 mg/m2 on days 1 to 4 and 5-FU 1000 mg/m2 i.v. on days 1 to 4 every 28 days).
  • Distant metastases were fairly balanced in the three arms (A: 14; B: 9; C: 11), with a tendency towards more frequent isolated distant metastasis development in arm C (8 of 11 [72%] versus 7 of 23 [30%] in arms A+B).
  • The 13 second tumors were equally distributed and were mainly correlated with tobacco and alcohol consumption (five lung, two esophagus, two oral cavity, one larynx, one pancreas, one hepatocarcinoma, one myeloma).
  • Arm C showed slightly more G3+ late side effects involving subcutaneous tissues and mucosa, although significant late sequelae were relatively uncommon and the mucosal side effects were mostly transient.
  • The occurrence of persistent G3 xerostomia was comparable in the three treatment arms.
  • CONCLUSIONS: The results obtained with the combination of CT and RT compared with RT alone did not reach statistical significance, but combined treatment almost doubled the five-year overall survival, relapse-free survival and locoregional control rate.
  • Patients with advanced squamous cell carcinomas of the oropharynx who are medically suitable for the combined approach should be treated with a combination of radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Risk Factors. Salvage Therapy. Survival Analysis. Time Factors. Treatment Failure. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683383.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Mesía R, Majem M, Barretina Ginesta MP, Galiana R, Mañós M, Guedea F, Montes A, Monner A, Pérez J, Cardenal F: Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy. Cancer Radiother; 2008 Mar;12(2):88-95
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy.
  • PURPOSE: The contribution of induction chemotherapy (CT) followed by hyperfractionated radiotherapy (hfRT) in unresectable squamous head and neck cancer has been evaluated in a single institution as an assistencial protocol.
  • All of them had stage IV-M0 disease: 67 T4, 88 N2-N3.
  • Tumor location: 62 oropharynx, 22 hypopharynx, eight oral cavity and seven larynx.
  • Tumor response at the end of treatment: 61 patients complete response, 17 partial response, two stable disease, 10 progressive disease and nine unevaluated.
  • With a median follow-up of 70 months the 5-year loco-regional control and overall survival was 30.3% (95% CI: 21.9-38.6) and 21.6% (95% CI: 13.4-29.8), respectively.
  • Chronic toxicity related to hfRT: six emergency tracheotomies due to laryngeal edema, five pneumonia and one mucous/soft-tissue necrosis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155633.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G: Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol; 2010 Nov;46(11):818-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
  • The aim of the present study was to identify a potentially effective new treatment regimen for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in disease progression after at least two previous chemotherapy regimens.
  • The regimen was administered to patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with surgery, radiotherapy or both and progressing after at least two chemotherapy regimens.
  • Twenty-four patients with histologically confirmed tumors of oral cavity, oropharynx, hypopharynx and larynx were enrolled.
  • All patients were stage IV and 91.6% had an ECOG PS 0-1.
  • After 3 cycles of treatment 23 patients (95.8%) were evaluable for response: 4 patients had partial response; 12 stable disease and 7 progressive disease.
  • The present study shows that the combination of Vinorelbine and Cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck patients is effective, feasible and has a good safety profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20920877.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 5V9KLZ54CY / Vinblastine; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


23. Pradier O, Eberlein K, Weiss E, Jackel MC, Hess CF: Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer. Br J Radiol; 2001 Apr;74(880):368-74
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.
  • The feasibility and effectiveness of a combined chemoradiotherapy treatment modality for locally advanced head and neck cancer was tested in a phase II trial.
  • From March 1995 to June 1998, 35 patients with advanced squamous cell carcinoma of the head and neck were treated with a continuous intravenous infusion of 5-fluorouracil (600 mg m-2 24 h-1 for Days 1 to 5 (120 h)) and mitomycin-C (10 mg m-2 intravenously) on Day 5 during the first week of radiotherapy and on Day 36.
  • 31 patients had stage IV disease; 4 patients had stage III; and 1 patient had stage II.
  • The tumours involved were as follows: oral cavity (n = 11); oropharynx (n = 14); hypopharynx/larynx (n = 10).
  • Radiotherapy was delivered to a total dose of 70 Gy with conventional fractionation (2 Gy per fraction, five times a week).
  • Chemotherapy was well tolerated and all patients received the intended dose.
  • When a recurrence appeared, it was within the first year after treatment.
  • We observed a treatment interruption of maximum 1 week for six patients owing to mucositis.
  • The concomitant use of 5-fluorouracil, mitomycin-C and radiotherapy in locally advanced head and neck carcinoma is well tolerated in this group of patients.
  • This protocol showed good locoregional response with a very low toxicity profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Mitomycin / administration & dosage. Radiation Dosage. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387156.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM: Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1087-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
  • PURPOSE: Pretreatment anemia is an adverse prognostic variable in squamous cell head-and-neck cancer (HNC) patients treated with radiotherapy (RT) alone.
  • Tumor hypoxia is an adverse parameter for treatment with RT alone or with RT and concurrent chemotherapy (CCT).
  • This study was performed to evaluate whether pretreatment Hgb less than 13 g/dL was correlated with treatment outcome in patients with advanced HNC treated with a uniform regimen of RT/CCT.
  • METHODS AND MATERIALS: The study population consisted of patients with AJCC Stage III or IV, M0 HNC who were treated with 70 to 72.5 Gy accelerated hyperfractionated RT (1.25 Gy b.i.d.) and CCT consisting of 2 cycles of CDDP (12-20 mg/m(2)/d x 5 days) and continuous infusion 5-FU (600 mg/m(2)/d x 5 days) during Week 1 and Week 6.
  • These patients were enrolled on the experimental arm of a prospective randomized trial that compared this regimen to hyperfractionated irradiation alone from 1990 to 1996.
  • RT/CCT was delivered as standard therapy from 1996 to 2000.
  • Primary tumor sites included oropharynx (43%), hypopharynx/larynx (36%), oral cavity (9%), and nasopharynx (6%).
  • Seventy-eight percent of the patients with Hgb 13 g/dL or higher and 92% of the patients with Hgb less than 13 g/dL had a primary tumor stage of T3 or T4 (p = 0.01).
  • The therapeutic effect of anemia correction is being evaluated in prospective trials.
  • [MeSH-major] Anemia / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Failure

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752888.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Franchin G, Vaccher E, Gobitti C, Minatel E, Politi D, Talamini R, Di Gennaro G, Savignano G, Trovò MG, Tirelli U, Barzan L: Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncol; 2005 May;41(5):526-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
  • A prospective phase II trial was carried out to evaluate an accelerated chemotherapy (CT) regimen followed by hyperfractionated radiation therapy (RT) in previously untreated Stage III-IV, operable (total laryngectomy), head and neck cancer patients.
  • Sixty patients received the planned RT-CT treatment.
  • The accelerated CT-RT regimen achieves a high rate of larynx preservation albeit with considerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Mouth Mucosa / radiation effects. Prospective Studies. Radiation Injuries / etiology. Radiotherapy / adverse effects. Stomatitis / etiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878759.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Loré JM Jr, Kaufman S, Sundquist N, Chary KK: Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy. Ann Surg Oncol; 2003 Jul;10(6):645-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
  • BACKGROUND: A 5- to 20-year evaluation of preoperative chemotherapy uncompromised surgery and selective radiotherapy in stage III/IV head and neck squamous cell carcinoma.
  • Sites included the oral cavity, oropharynx, larynx, and hypopharynx.
  • The extent of surgery was carefully documented before chemotherapy-tattoo when feasible.
  • CONCLUSIONS: This study suggests treatment of advanced head and neck squamous cell carcinoma (resectable for cure) with preoperative chemotherapy (regimen B); resection of original tumor volume, regardless of response to chemotherapy; and selective (rather than routine) postoperative radiotherapy results in improved survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2003 Jul;10(6):593-5 [12839842.001]
  • (PMID = 12839849.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Rivera F, Vega-Villegas ME, López-Brea M, Isla D, Mayorga M, Galdós P, Rubio A, Del Valle A, García-Reija F, García-Montesinos B, Rodríguez-Iglesias J, Mayordomo J, Rama J, Saiz-Bustillo R, Sanz-Ortiz J: Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). Cancer Chemother Pharmacol; 2008 Jul;62(2):253-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
  • OBJECTIVES: We conducted a multicentric randomized phase II trial comparing 5-FU continuous infusion (PF) and cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy (IC) in locally advanced squamous cell head and neck cancer (LA-SCHNC).
  • RESULTS: A total of 206 patients (pts) were included (PF/UFTVP: 99/107): oral cavity: 8%/10%, oropharynx: 20%/25%, hypopharynx: 17%/14%, larynx: 54%/50%.
  • Stage (TNM, 2002): III: 41%/35%, IVA: 23%/27%, IVB: 35%/38%.
  • IC with UFTVP was associated with a favourable OS in the Cox analysis (actuarial 5 year OS: 49% vs. 34%; HR: 0.67, 95% CI: 0.47-0.95, P: 0.03).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease-Free Survival. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Tegafur / administration & dosage. Tegafur / adverse effects. Tegafur / therapeutic use. Uracil / administration & dosage. Uracil / adverse effects. Uracil / therapeutic use. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use


28. Kubota A, Furukawa M, Komatsu M, Hanamura H, Sugiyama M: [Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Mar 20;109(3):149-56
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
  • To evaluate the efficacy of adjuvant chemotherapy after concurrent chemoradiotherapy, 41 previously untreated patients with locally advanced and resectable head and neck squamous cancer were enrolled in a study to compare adjuvant chemotherapy (Nedaplatin/UFT) after concurrent chemoradiotherapy (CDDP/5-FU) and concurrent chemoradiation alone.
  • Nine of the patients had stage III tumors and 32 had stage IV tumors.
  • The primary tumor site was the hypopharynx in 14 patients, the larynx in 12 patients, the oral cavity in 9 patients, and the oropharynx in 6 patients.
  • Treatment consisted of 6 courses of Nedaplatin (80 mg/m2) repeated at 4-week intervals and one year of the oral administration of UFTE (400 mg/day) after concurrent chemoradiotherapy at an outpatient clinic.
  • The median overall survival time was 30.1 months (5.5-50.1 months) for the adjuvant chemotherapy group and 21.7 months (4.0-48.8 months) for the control group.
  • The progression-free survival period was 22.8 months (5.6-33.9 months) for the adjuvant chemotherapy group and 26.5 months (5.6-33.9 months) for the control group.
  • The two-year overall survival rate was 73.3% for the adjuvant chemotherapy group and 55.7% for the control group.
  • A significant difference was observed in the two-year progression-free survival rates: 66.9% for the adjuvant chemotherapy group and 27.8% for the control group (p = 0.03290).
  • Among the patients with a partial response to concurrent chemoradiotherapy, in particular, a significant difference in the two-year progression-free survival rates was seen : 59.3% for the adjuvant chemotherapy group and 15.3% for the control group (p = 0.01102).
  • The rate of loco-regional failure was 29.6% for the adjuvant chemotherapy group and 64.3% for the control group (p = 0.0716).
  • The rate of organ preservation was 66.7% for the adjuvant chemotherapy group and 35.7% for the control group (p = 0.1183).
  • This adjuvant chemotherapy regimen might improve the loco-regional control rates after concurrent chemoradiotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615429.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Wolf GT, Bradford CR, Urba S, Smith A, Eisbruch A, Chepeha DB, Teknos TN, Worden F, Dawson L, Terrell JE, Hogikyan ND: Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer. Laryngoscope; 2002 Aug;112(8 Pt 1):1351-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer.
  • OBJECTIVE: To determine whether pretreatment lymphocyte subpopulations correlate with tumor response to induction chemotherapy as part of an organ preservation treatment approach in patients with advanced laryngeal cancer.
  • STUDY DESIGN: A prospective clinical trial in patients with advanced laryngeal cancer was undertaken to determine whether the frequency of late salvage laryngectomy and overall survival could be improved using one cycle of neoadjuvant chemotherapy to select patients for organ preservation.
  • Pretreatment peripheral blood lymphocyte subpopulations for CD3, CD4, CD8, NK, and B cells were correlated with tumor response to induction chemotherapy, larynx preservation, and survival, to determine whether immune parameters could be useful in patient selection.
  • Studied were 53 patients with stage III (42%) or IV (57%) larynx cancer.
  • Sixty-eight percent had greater than 50% tumor response after one cycle of induction chemotherapy and then received concurrent chemoradiation and two cycles of adjuvant chemotherapy.
  • Only 4 cases were late salvage resections (13-35 mo after treatment).
  • Fourteen cases were planned surgery after initial chemotherapy.
  • Of the lymphocyte subpopulations measured, CD8 levels were significantly lower in stage IV patients and tended to be lower in patients with successful organ preservation.
  • However, no significant differences in lymphocyte subpopulations were found among responders and nonresponders to chemotherapy.
  • CONCLUSIONS: One cycle of neoadjuvant chemotherapy was effective in selecting patients for organ preservation.
  • The regimen of definitive concurrent and adjuvant chemotherapy was associated with an unexpectedly high 2-year survival rate.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / immunology
  • [MeSH-minor] Chemotherapy, Adjuvant. Follow-Up Studies. Humans. Laryngectomy. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172244.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-46592-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


30. Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I: Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer; 2001 Sep 1;93(5):725-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
  • Moreover, their influence on response to chemotherapy in cancer patients has been demonstrated.
  • To investigate the role of GST enzymes in carcinogenesis and in response to chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC), GSTP1, GSTM1 and GSTT1 were studied prospectively in a large series of HNSCC patients.
  • Correlations between GST alterations, p53 mutation status and clinical response to chemotherapy were investigated.
  • We showed that the risk of developing laryngeal cancer was increased by 2.6-fold [95% CI 1.6--6.1] in patients with the GSTM1 null genotype and by 2.8-fold [95% CI 0.9--8.1] in patients with the homozygous GSTP1 val105 genotype.
  • Two types of multivariate analysis were performed including parameters that have been shown to influence response to chemotherapy significantly in univariate analysis. p53 mutations and high tumor stage are independent factors of non-response to chemotherapy, whereas plasmatic GSTP1 levels and low tumor stage are independent factors of complete response.
  • Our data suggest that GST enzymes are associated with larynx cancer and that their use as predictive factors and treatment targets should be further explored.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Glutathione Transferase / blood. Head and Neck Neoplasms / enzymology. Isoenzymes / blood
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Gene Frequency. Genotype. Glutathione S-Transferase pi. Humans. Male. Middle Aged. Multivariate Analysis. Mutation. Neoadjuvant Therapy. Treatment Outcome. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11477586.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoenzymes; 0 / Tumor Suppressor Protein p53; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Jeremić B, Milicić B: Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol; 2009 Apr;32(2):163-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
  • BACKGROUND: Identification of pretreatment prognostic factors influencing overall survival (OS) in locally advanced squamous cell carcinoma of the head and neck is an important issue in head and neck oncology.
  • METHODS: A total of 289 patients were treated with standard fraction or hyperfractionated radiation therapy with or without concurrent low-dose daily chemotherapy.
  • RESULTS: Gender (P = 0.43) and age (P = 0.26) did not influence OS whereas Karnofsky Performance Status (KPS) (P < 0.0001), T stage (P < 0.0001), and N stage (P < 0.0001) did.
  • Stage grouping was another factor that influenced OS (P < 0.001).
  • Patients with larynx and nasopharynx fared better than those with other primaries (P = 0.0153).
  • Finally, treatment significantly influenced OS.
  • Multivariate analysis showed that KPS, T and N stage, and treatment were independent prognosticators of OS.
  • CONCLUSIONS: KPS, T and N stage, and treatment are independent prognosticators of OS in patients with locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent low-dose daily chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Radiotherapy Dosage
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Randomized Controlled Trials as Topic. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307954.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Herchenhorn D, Dias FL, Ferreira CG, Araújo CM, Lima RA, Small IA, Kligerman J: Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation. ORL J Otorhinolaryngol Relat Spec; 2008;70(6):381-8
MedlinePlus Health Information. consumer health - Choking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation.
  • HYPOTHESIS: The combination of chemotherapy and radiotherapy is a standard nonsurgical treatment for locally advanced laryngeal cancer.
  • Nevertheless, there are no validated markers to predict the outcome of nonsurgical therapies.
  • Prognostic factors such as stage, age, performance status, number of chemotherapy cycles, radiotherapy dose, stage VIb disease, and previous tracheotomy were analyzed using the Cox's proportional hazard model.
  • PATIENTS AND METHODS: Patients with stage III/IV laryngeal carcinoma were prospectively selected.
  • Treatment consisted of cisplatin 100 mg/m(2) every 3 weeks for 3 cycles, radiotherapy to a total dose of 70.2 Gy and salvage surgery.
  • RESULTS: Forty-nine patients were analyzed; tracheotomy was performed in 12 patients (24.5%) before therapy.
  • CONCLUSIONS: Previous tracheotomy is a negative prognostic factor for patients submitted to chemotherapy combined with radiotherapy and should be considered as a negative clinical prognostic factor in the selection of patients for more aggressive treatment strategies.
  • [MeSH-major] Airway Obstruction / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Tracheotomy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18984974.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Franzen A, Kurrer MO: [Malignant lymphoma of the larynx: a case report and review of the literature]. Laryngorhinootologie; 2000 Oct;79(10):579-83
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the larynx: a case report and review of the literature].
  • [Transliterated title] Das maligne Lymphom des Larynx: Fallbericht und Literaturübersicht.
  • BACKGROUND: Malignant lymphoma of the larynx are rare tumors and represent less than 1% of primary malignant laryngeal tumors.
  • CASE REPORT: In this case report we present a case of a diffuse large B-cell lymphoma of the larynx.
  • Clinical presentation, diagnostic approach, staging and differential diagnosis as well as therapy and prognosis are discussed in relation to the available literature.
  • CONCLUSIONS: Lymphomas primary to the larynx are non-Hodgkin-lymphomas and are predominantly located in the supraglottic larynx.
  • The diagnosis rests on histological examination of a biopsy specimen.
  • Benign tumors, squamous cell carcinoma and other lymphoproliferative diseases have to be excluded from the differential diagnosis.
  • Extensive tumor staging is necessary before radiotherapy or chemotherapy.
  • Prognosis is good in the most often localized laryngeal non-Hodgkin-lymphomas (stage IE and IIE) and generalization is rare.
  • Hence, supraglottic submucosal laryngeal tumors can represent non-Hodgkin-lymphomas.
  • [MeSH-major] Laryngeal Neoplasms. Lymphoma, B-Cell
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Laryngoscopy. Larynx / pathology. Male. Prednisone / therapeutic use. Prognosis. Radiotherapy Dosage. Terminology as Topic. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11089205.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


34. Leu YS, Hsiao HT, Chang YC, Yang CC, Lee JC, Chen YJ, Chang YF: Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report. Acta Otolaryngol; 2005 Jun;125(6):642-6
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report.
  • CONCLUSION: The new technique of ileocolic free flap reconstruction provides a better quality of life in terms of swallowing and speech for patients who have undergone laryngopharyngectomy with concomitant chemotherapy and radiotherapy (CCRT).
  • MATERIAL AND METHODS: This was a follow-up study of 12 patients with advanced (stages III, IVA and IVB) laryngeal and hypopharyngeal cancer who underwent major surgery, CCRT (with one exception) and ileocolic free flap reconstruction.
  • RESULTS: All patients were able to tolerate single-stage combined management comprising total laryngopharyngectomy with or without radical neck dissection plus ileocolic free flap reconstruction and postoperative CCRT (with one exception), without immediate morbidity or mortality.
  • Eleven patients were diagnosed with hypopharyngeal cancer and one with laryngeal cancer.
  • [MeSH-major] Colon / transplantation. Deglutition / physiology. Hypopharyngeal Neoplasms / surgery. Ileocecal Valve / transplantation. Laryngeal Neoplasms / surgery. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Speech / physiology. Surgical Flaps
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Follow-Up Studies. Humans. Laryngectomy / rehabilitation. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pharyngectomy / rehabilitation. Quality of Life. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076714.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R: Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol; 2005 Aug;28(4):371-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
  • OBJECTIVES: The authors reviewed records of patients with advanced laryngeal cancer treated with induction chemotherapy (IC) and hyperfractionated radiation therapy (RT) or chemoradiation (CRT) to determine the rates of organ preservation and function.
  • METHODS: A total of 29 patients with stage III (45%) and stage IV (55%) squamous cell carcinoma of the larynx (SCCL), were treated with IC and RT or CRT in 1 of 7 consecutive trials.
  • Relapse occurred in 12 patients (41%), and 6 underwent salvage laryngectomy (5 stage III, 1 stage IV).
  • Fifty-nine percent of patients (17 of 29) are alive at last follow-up with an anatomically intact larynx, and 48% (14 of 29) are alive with a functional larynx.
  • Of the 23 patients for whom detailed information on gastrostomy tube (g-tube) placement/removal was available, median time with g-tube was 12 months, and 15 of 23 patients (65%) had a g-tube for 6 months or more.
  • Twenty-three of all 29 patients (79%) retained an anatomically intact larynx, but 7 of 23 (30%) never resumed their pretreatment organ function.
  • The 7 of 29 patients (26%) who retained a nonfunctional larynx required permanent g-tube or were unable to return to pretreatment oral intake capability.
  • Nine of 13 with T4 SCCL (69%) compared with 7 of 16 (44%) T3 SCCL retained a functional larynx.
  • CONCLUSION: The rate of larynx preservation is high, but toxicity remains significant with IC followed by hyperfractionated RT or CRT in advanced laryngeal cancer.
  • Half of all patients were alive, able to retain their larynx, and return to pretreatment function.
  • Advanced stage was not an indicator of poor outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Stenosis / prevention & control. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Dose Fractionation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Laryngectomy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062079.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):461-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy.
  • PURPOSE: To report the treatment outcomes of definitive radiotherapy (RT) for early-stage squamous cell carcinoma (SCCA) of the glottic larynx.
  • METHODS AND MATERIALS: We retrospectively reviewed the medical records of 585 patients with T1N0 to T2N0 invasive SCCA of the glottic larynx treated between 1964 and 2006 with RT alone.
  • None of these patients received chemotherapy or had elective nodal RT.
  • The probabilities of local control (LC), ultimate LC, ultimate LC with larynx preservation, neck control, cause-specific survival (CSS), and overall survival (OS) were calculated by the Kaplan-Meier product-limit method.
  • Multivariate analysis revealed that overall treatment time greater than 41 days (p = 0.001) and poorly differentiated histology (p = 0.016) adversely affected LC.
  • Five-year rates of ultimate LC with laryngeal preservation were: T1A, 95%; T1B, 94%, T2A, 81%; and T2B, 74%.
  • One patient died of a radiation-induced carotid artery angiosarcoma.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Glottis / pathology. Glottis / surgery. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Radiation Injuries / complications. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153124.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB, Nam SY, Kim SY: 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol; 2007 Aug;33(6):790-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx.
  • Pretreatment FDG uptake was evaluated as a predictor of survival and guidance for primary surgery or radiotherapy (RT) in patients with squamous cell carcinoma (SCC) of the larynx and hypopharynx.
  • MATERIALS AND METHODS: Seventy-nine consecutive patients with newly diagnosed advanced resectable SCC of the larynx and hypopharynx underwent FDG positron emission tomography (PET) before surgical resection plus RT and chemotherapy (surgery group, n=40) or RT with chemotherapy and surgical salvage (RT group, n=39).
  • Age, tumor stage, histological grade, treatment strategy, and standardized uptake value (SUV) were analyzed for association with local control and survival.
  • When patients with SUV>8.0 in the two treatment groups were analyzed separately, those in the surgery group tended to have a higher 3-year DFS than those in the RT group, despite no statistical significance (48% vs. 27%, P=0.085).
  • Patients with high FDG uptake may be better treated by surgical resection followed by RT and chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Fluorodeoxyglucose F18. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / surgery. Patient Care Planning. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Forecasting. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiotherapy, Adjuvant. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306956.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


38. Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H: Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol; 2006 Jun;120(6):478-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx.
  • This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx.
  • Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66-72 Gy.
  • The three-year overall survival rate with larynx preservation was 100 per cent.
  • Concurrent chemoradiotherapy with carboplatin and UFT for stage two SCC of the glottic larynx was safe and effective in improving local control with larynx preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563197.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin
  •  go-up   go-down


39. Erisen LM, Coskun H, Ozuysal S, Basut O, Onart S, Hizalan I, Tezel I: Basaloid squamous cell carcinoma of the larynx: a report of four new cases. Laryngoscope; 2004 Jul;114(7):1179-83
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the larynx: a report of four new cases.
  • OBJECTIVES: This study is designed to report the clinical and pathologic features and outcome of cases of basaloid squamous cell carcinoma (BSCC) of the larynx treated in our clinic.
  • METHODS: Four cases of BSCC of the larynx were treated in our department.
  • RESULTS: All patients were male (mean 57), with supraglottic or transglottic larynx tumors.
  • Two patients presented with stage-II disease and the other 2 with stage-IV disease.
  • Initial diagnosis was invasive squamous cell carcinoma in 3 patients and BSCC in one patient.
  • Two patients who had stage-II disease underwent partial laryngectomy and bilateral neck dissections; total laryngectomy and bilateral neck dissections were performed in stage-IV patients.
  • Three patients received adjuvant postoperative radiotherapy, and 2 of them also received additional chemotherapy.
  • Patients with stage-IV disease were found to have 4 and 27 metastatic lymph nodes on histopathologic examination and died because of distant metastases at 11 and 14 months, respectively.
  • Patients with stage-II disease did not have cervical metastasis on histopathologic examination and were alive and free of disease at 52 and 72 months respectively.
  • CONCLUSION: In contrast with the literature reporting the tendency of more aggressive clinical behavior of the BSCC, we can say that BSCC has a behavior similar to conventional squamous cell carcinoma based on our 4 cases.
  • [MeSH-major] Carcinoma, Basosquamous / therapy. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Immunohistochemistry. Male. Middle Aged. Neck Dissection. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15235344.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Hinerman RW, Morris CG, Amdur RJ, Lansford CD, Werning JW, Villaret DB, Mendenhall WM: Surgery and postoperative radiotherapy for squamous cell carcinoma of the larynx and pharynx. Am J Clin Oncol; 2006 Dec;29(6):613-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and postoperative radiotherapy for squamous cell carcinoma of the larynx and pharynx.
  • OBJECTIVE: To determine the rates of local-regional control, survival, and complications for patients treated with postoperative radiation for squamous carcinomas of the larynx, hypopharynx, and oropharynx.
  • METHODS: There were 295 patients with previously untreated squamous cell carcinomas of the larynx (n = 199), hypopharynx (n = 80), and oropharynx (n = 16) treated postoperatively with radiotherapy (RT).
  • RESULTS: Five-year local-regional control rates according to site and pathologic American Joint Committee on Cancer (AJCC) stage were: stage III larynx, 89% versus stage IVA larynx, 85% (P = 0.33); stage III oropharynx/hypopharynx, 76% versus stage IVA oropharynx/hypopharynx, 79% (P = 0.72).
  • Five-year absolute survival rates versus pathologic AJCC stage for the entire group were: stage III 59% and stage IVA 40% (P = 0.40).
  • Tumor control and survival will hopefully improve further with the addition of chemotherapy to postoperative radiation.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149000.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):410-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
  • PURPOSE: To review the University of Iowa experience with intensity-modulated radiotherapy (IMRT) in the treatment of head-and-neck squamous cell carcinoma.
  • METHODS AND MATERIALS: From October 1999 to April 2004, 151 patients with head-and-neck squamous cell carcinoma were treated with IMRT for curative intent.
  • One patient was lost to follow-up 2 months after treatment and therefore excluded from analysis.
  • Of the remaining 150 patients, 99 were treated with definitive IMRT, and 51 received postoperative IMRT.
  • Sites included were nasopharynx, 5; oropharynx, 56; larynx, 33; oral cavity, 29; hypopharynx, 8; nasal cavity/paranasal sinus, 8; and unknown primary, 11.
  • None of the patients treated with postoperative IMRT received chemotherapy.
  • Of 99 patients who had definitive IMRT, 68 patients received concurrent cisplatin-based chemotherapy.
  • One patient received induction cisplatin-based chemotherapy, but no concurrent chemotherapy was given.
  • The prescribed doses to CTV1, CTV2, and CTV3 in the definitive cohort were 70-74 Gy, 60 Gy, and 54 Gy, respectively.
  • For high-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 64-66 Gy, 60 Gy, and 54 Gy, respectively.
  • For intermediate-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 60 Gy, 60 Gy, and 54 Gy.
  • The median time from treatment completion to local-regional recurrence was 4.7 months (range, 1.8 to 15.6 months).
  • Patients with oropharyngeal cancer did significantly better than patients with oral cavity and laryngeal cancer, with a 2-year local-regional control rate of 98%, compared with 78% for oral cavity cancer and 85% for laryngeal cancer (p = 0.005).
  • There was no significant difference in local-regional control for patients who received postoperative radiation or definitive radiation (p = 0.339) and for patients who had chemotherapy or not (p = 0.402).
  • Neither T stage nor N stage had a significant effect on local-regional control (p = 0.722 and 0.712, respectively).
  • More studies are necessary to further improve the outcomes of laryngeal cancer as well as oral cavity cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Iowa. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Failure. Universities

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


42. Morales-Puebla JM, Toro-Rojas M, Segura-Saint-Gerons R, Fanego-Fernández J, López-Villarejo P: Basaloid squamous cell carcinoma: report of five cases. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e451-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: report of five cases.
  • OBJECTIVES: To document the clinical and histopathological characteristics of basaloid squamous cell carcinoma (BSCC).
  • CASES: retrospective review of five cases with the diagnosis of BSCC of the larynx.
  • Three patients presented with stage-IV disease and the other two with stage-I disease.
  • Surgery supplemented with radiation was used in three patients, partial surgery was used in another case and radiation and associated chemotherapy in the other one.
  • Central comedonecrosis within the cells nests, cell with nuclear palisading and high-grade dysplasia in overlaying mucosa are the main characteristics.
  • [MeSH-major] Carcinoma, Squamous Cell. Laryngeal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038913.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


43. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, Rosenthal DI, Gillison M, Forastiere AA: Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol; 2007 Sep 1;25(25):3971-7
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
  • This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (OP) cancer patients.
  • PATIENTS AND METHODS: Eligibility required resectable stage T2N+, or T3-T4N0-3M0 biopsy-proven squamous carcinoma, age at least 18 years, PS 0 to 2, good organ function, and no prior chemotherapy or radiation.
  • Treatment was induction paclitaxel 175 mg/m(2) and carboplatin area under the concentration-time curve (AUC) 6 for two cycles every 21 days followed by concurrent paclitaxel 30 mg/m(2) every 7 days with 70 Gy if no evidence of tumor progression.
  • RESULTS: One hundred five of 111 patients (36 larynx, 69 OP) were eligible.
  • No patient progressed while receiving chemotherapy.
  • Organ preservation was 81% at 2 years after completion of therapy (larynx 74%, OP 84%).
  • Thirteen patients required primary-site salvage surgery (seven larynx, six OP), and six of these have progressed and died (three larynx, three OP).
  • Thirteen patients developed distant metastases (seven larynx, six OP; P = .02) and 10 of 36 larynx and 11 of 69 OP patients have died as a result of their disease.
  • Two-year survival is 76% (63% larynx v 83% OP).
  • CONCLUSION: A high organ preservation rate was obtained with this regimen for OP but not for larynx patients.
  • Toxicity was low, and induction chemotherapy did not preclude delivery of concurrent chemoradiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bridged Compounds / administration & dosage. Chemotherapy, Adjuvant. Deglutition Disorders / etiology. Deglutition Disorders / prevention & control. Female. Follow-Up Studies. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pharyngectomy. Platinum / administration & dosage. Radiotherapy, Adjuvant. Recovery of Function. Salvage Therapy. Speech Disorders / etiology. Speech Disorders / prevention & control. Taxoids / administration & dosage. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane; 49DFR088MY / Platinum; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


44. Sas-Korczynska B, Korzeniowski S, Skolyszewski J: Cancer of the larynx in females. Cancer Radiother; 2003 Dec;7(6):380-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the larynx in females.
  • PURPOSE: The aim of this paper is to present results of analysis of 102 females with laryngeal cancer.
  • MATERIALS AND METHODS: Between 1974 and 1995, 102 female patients with cancer of larynx were treated at Radiotherapy Department of Oncology Centre in Kraków.
  • The treatment method depended on stage of disease.
  • Primary radical irradiation was performed in 66 patients, 29 patients received postoperative radiotherapy after surgery (total or partial laryngectomy), seven patients received induction chemotherapy followed by laryngectomy with postoperative radiotherapy or radical irradiation.
  • The median dose applied with radiotherapy was 60 Gy, and dose per fraction was 2 Gy.
  • Only tumour stage and nodal involvement were found to be significant factor for all three endpoints.
  • CONCLUSIONS: The tumour stage and nodal involvement were found to be significant prognostic factors in analysed group of female treated with laryngeal cancer.
  • [MeSH-major] Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Follow-Up Studies. Humans. Laryngectomy. Larynx / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Postoperative Care. Prognosis. Radiotherapy Dosage. Sex Factors. Smoking / adverse effects. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14725911.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


45. Kumar M, Bahl A, Sharma DN, Sharma R, Gupta R, Ahmed S, Julka PK, Rath GK: Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma. J Cancer Res Ther; 2009 Apr-Jun;5(2):124-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma.
  • Cylindric cell carcinomas (transitional cell carcinomas) are a rare and distinct histopathological entity presenting in the head and neck region.
  • They have been known by myriads of nomenclature like cylindric carcinomas, nonkeratinizing sinonasal carcinoma, papillary carcinoma, cylindrical or columnar cell carcinoma, intermediate cell carcinoma, Schneiderian carcinoma, and Ringertz carcinoma.
  • They are considered a variant of nonkeratinizing squamous cell carcinoma.
  • Cylindric carcinomas are usually described in the sinus and nasal cavity and rarely said to involve nasopharynx and larynx.
  • We report here a rare case of transitional cell carcinoma presenting in the base of the tongue.
  • There are no separate treatment recommendations in the literature, and the management is on the lines of treatment of squamous cell carcinoma.
  • We report here a case of cylindric cell carcinoma presenting in the base of the tongue.
  • The patient was staged as having cT2 N3 M0 (Stage IV B) disease.
  • The patient received palliative radiotherapy of 20 Gy in five fractions followed by chemotherapy with injection paclitaxel and carboplatin.
  • A partial response to treatment was achieved at the time of writing this report.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542670.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


46. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 95 cases of squamous cell carcinoma of the external and middle ear.
  • OBJECTIVE: To analyze the clinical characteristics, 5-year survival, and prognostic factors of squamous cell carcinoma (SCC) of the external and middle ear.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • RESULTS: This disease seems to appear in the elderly with a peak age of 50-69 years.
  • Males appear to be more predisposed than females with an odd ratio of 1.7.
  • SCC located in the external ear could be detected in an earlier stage than that in the middle ear.
  • The overall 5-year survival was 66.8% in total, and decreased significantly with stage.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • Stage, completeness of operation with tumor free margin, recurrence, and metastasis have significant influence on survival.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • Tumor stage adds more influence on survival than its location.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Ear Neoplasms / epidemiology. Ear, External. Ear, Middle

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Abitbol A, Abdel-Wahab M, Lewin A, Troner M, Rodrigues MA, Hamilton-Nelson KL, Markoe A: Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):942-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
  • PURPOSE: To determine the toxicity and efficacy of concurrent 5-fluorouracil (5-FU), cisplatin, and paclitaxel (Taxol) and hyperfractionated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
  • Eligible patients had Stage III or IV head-and-neck squamous cell carcinoma arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx.
  • The plan of treatment consisted of hyperfractionated radiotherapy (74.4 Gy at twice daily fractions of 1.2 Gy).
  • Chemotherapy was given on Weeks 1, 5, and 8 as follows: 5-FU at 750 mg/m2 as a constant infusion for 24 h for 3 days; cisplatin at 50 mg/m2 in 250-500 mL D5 0.5 NS or NS infusion during 2-4 h, and paclitaxel at 70 mg/m2 infused in 500 mL NS during 3 h.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cisplatin / therapeutic use. Dose Fractionation. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Paclitaxel / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12095561.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Fornari G, Artusio E, Mairone L, Airoldi M, Bongioannini G, Amasio E, Rosmino C, Gabriele P: Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori; 2002 Nov-Dec;88(6):489-94
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
  • AIM AND BACKGROUND: To evaluate feasibility of neoadjuvant chemotherapy (NA-CT) followed by CT + radiotherapy (RT) in locally advanced or unresectable head and neck squamous cell carcinoma (HNSCC).
  • Sites of disease: oral cavity, 18.2%; oropharynx, 40.9%; hypopharynx, 18.2%; larynx, 4.6%, multiple sites, 18.2%.
  • Stage: III, 4.6%; IVA, 63.6%; IVB, 31.8%.
  • Responders received definitive radiotherapy with concurrent carboplatin (35 mg/m2/day from days 1 to 5 in weeks 1, 3, 5 and 7) and paclitaxel (50 mg/m2 on days 10, 24 and 38).
  • 97% of planned chemotherapy cycles were administered.
  • Median dose of RT was 70.2 Gy on T/N+ and 54 Gy on NO.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy / adverse effects. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant / adverse effects. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597144.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


49. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the head and neck.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Their ages ranged from 43 to 85 years, with a mean age of 62 years.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


50. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst; 2008 Feb 20;100(4):261-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
  • BACKGROUND: The improved prognosis for patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC observed in retrospective analyses remains to be confirmed in a prospective clinical trial.
  • METHODS: We prospectively evaluated the association of tumor HPV status with therapeutic response and survival among 96 patients with stage III or IV HNSCC of the oropharynx or larynx who participated in an Eastern Cooperative Oncology Group (ECOG) phase II trial and who received two cycles of induction chemotherapy with intravenous paclitaxel and carboplatin followed by concomitant weekly intravenous paclitaxel and standard fractionation radiation therapy.
  • The presence or absence of HPV oncogenic types in tumors was determined by multiplex polymerase chain reaction (PCR) and in situ hybridization.
  • The relative hazard of mortality and progression for HPV-positive vs HPV-negative patients after adjustment for age, ECOG performance status, stage, and other covariables was estimated by use of a multivariable Cox proportional hazards model.
  • RESULTS: Genomic DNA of oncogenic HPV types 16, 33, or 35 was located within tumor cell nuclei of 40% (95% confidence interval [CI] = 30% to 50%) of patients with HNSCC of the oropharynx or larynx by in situ hybridization and PCR.
  • Compared with patients with HPV-negative tumors, patients with HPV-positive tumors had higher response rates after induction chemotherapy (82% vs 55%, difference = 27%, 95% CI = 9.3% to 44.7%, P = .01) and after chemoradiation treatment (84% vs 57%, difference = 27%, 95% CI = 9.7% to 44.3%, P = .007).
  • After a median follow-up of 39.1 months, patients with HPV-positive tumors had improved overall survival (2-year overall survival = 95% [95% CI = 87% to 100%] vs 62% [95% CI = 49% to 74%], difference = 33%, 95% CI = 18.6% to 47.4%, P = .005, log-rank test) and, after adjustment for age, tumor stage, and ECOG performance status, lower risks of progression (hazard ratio [HR] = 0.27, 95% CI = 0.10 to 0.75), and death from any cause (HR = 0.36, 95% CI = 0.15 to 0.85) than those with HPV-negative tumors.
  • CONCLUSION: For patients with HNSCC of the oropharynx, tumor HPV status is strongly associated with therapeutic response and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / virology. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / virology. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Dose Fractionation. Drug Administration Schedule. Female. Humans. In Situ Hybridization. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Paclitaxel / administration & dosage. Polymerase Chain Reaction. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome


51. Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt ML: Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma. Oral Oncol; 2006 May;42(5):517-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
  • The aim of this study was to define the feasibility of a late chemo-intensification treatment regimen with conventionally fractionated radiotherapy (70 Gy/7 weeks).
  • Seventy four patients with Stage III and IV biopsy proven squamous cell carcinoma of oropharynx, hypopharynx and larynx were treated with this regimen.
  • Chemotherapy consisted of continuous infusion of 5-FU at 350 mg/m(2)/day and cisplatin as 1h infusion at 10 mg/m(2)/day on days 1-5 of week 6 and 7 of radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / methods. Dose Fractionation. Drug Administration Schedule. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480913.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Imauchi Y, Ito K, Takasago E, Nibu K, Sugasawa M, Ichimura K: Stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg; 2002 Jan;126(1):63-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx.
  • OBJECTIVE: Stomal recurrence after total laryngectomy is one of the most serious issues in the management of laryngeal carcinoma.
  • The management of stomal recurrence, including chemotherapy, radiotherapy, and surgery, has been reported as unsatisfactory.
  • STUDY DESIGN AND SETTING: From 1985 to 1995, 69 patients underwent total laryngectomy for the treatment of laryngeal cancer at the University of Tokyo Hospital.
  • RESULTS: Stomal recurrence developed in 6 of 69 patients who underwent total laryngectomy for laryngeal carcinoma.
  • CONCLUSION: Intensive follow-up should be performed for patients with glottic carcinoma who had preoperative tracheotomy, paratracheal lymph node metastasis, or both to detect stomal recurrence at an early stage.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Risk Factors. Salvage Therapy. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / epidemiology. Tracheal Neoplasms / secondary. Tracheotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11821768.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Kubota A, Furukawa M, Fujita Y, Yagi H: [Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy]. Nihon Jibiinkoka Gakkai Kaiho; 2010 Mar;113(3):101-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
  • We evaluated clinical factors associated with concurrent chemoradiotherapy (CRT) toxicity and efficacy in resectable locoregionally advanced squamous cell carcinoma of the head and neck.
  • Subject were 115 subjects with stage III or IV carcinoma undergooing 58 to 70 Gy of irradiation (median total dose: 66 Gy) concurrently with 2 cycles of chemotherapy of 5FU at 1000 mg/m2, 120-hour continuous infusion and cisplatin at 60 mg/m2.
  • No significant difference in planned therapy completion was seen between 87% in N0 and 82% in N1 to 2.
  • OS differed significantly between 86% in stage III and 57% in IV, 78% in T0 to 2 and 62% in T3 to 4, 83% in N0 to 1 and 53% in N2, 77% in adjuvant chemotherapy (nedaplatin plus UFT) and 50% in no adjuvant chemotherapy, and 33% in the tongue and 77% in the oropharynx.
  • PFS significantly differed between 72% in T0 to 2 and 49% in T3 to 4, 77% in CR and 53% in PR, and 22% in the tongue and 58% in the hypopharynx, 66% in the oropharynx, and 53% in the larynx.
  • Multivariable analysis showed strongly independent risk factors associated with OS and PFS to be advanced T and N stage, no adjuvant chemotherapy, and the tongue as the site.
  • CRT was effective in treating resectable locoregionally advanced squamous cell carcinoma of the head and neck.
  • It is possible that adjuvant chemotherapy will improve CRT OS and PFS.
  • Other additional treatment will be needed, however, to improve OS and PFS in cases having a dismal diagnosis such as tongue cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387597.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Devlin JG, Langer CJ: Combined modality treatment of laryngeal squamous cell carcinoma. Expert Rev Anticancer Ther; 2007 Mar;7(3):331-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality treatment of laryngeal squamous cell carcinoma.
  • Squamous cell carcinoma of the larynx is a major public health concern; it causes substantial morbidity and mortality, and arises chiefly as a result of tobacco and alcohol consumption.
  • Early stage disease is best treated with radiation or surgery alone, but for patients with more locally advanced squamous cell carcinoma of the larynx, combined modality treatment has been shown to benefit selected patients, particularly when cisplatin-based chemotherapy and concurrent radiation therapy are employed, with or without altered fractionated radiation therapy.
  • The addition of induction chemotherapy to concurrent chemoradiotherapy is a promising treatment strategy that warrants further evaluation, but has not yet emerged as a standard of care; the toxicity of such regimens must be balanced with the potential benefits on a case-by-case basis, and functional outcomes are often quite variable.
  • Treatment planning, management and follow-up are complex, and thus should ideally be performed in a comprehensive, multidisciplinary fashion, in a center accustomed to a high volume of such cases.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Division / radiation effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Management. Glottis / pathology. Humans. Incidence. Laryngectomy / adverse effects. Meta-Analysis as Topic. Neck Dissection. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Staging. Palliative Care. Positron-Emission Tomography. Quality of Life. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Treatment Outcome. Voice Disorders / etiology. Voice Disorders / prevention & control

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338653.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 131
  •  go-up   go-down


55. Teknos TN, Cox C, Barrios MA, Chepeha DB, Bradford CR, Fisher SG, Wolf GT: Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope; 2002 May;112(5):844-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.
  • BACKGROUND: The purpose of this study was to retrospectively investigate tumor angiogenesis as a predictive marker for response to neoadjuvant chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma.
  • METHODS: A total of 332 patients with stage III (188 patients) or stage IV (144 patients) squamous cell carcinoma of the larynx were entered in the prospective trial conducted by the Department of Veteran Affairs Laryngeal Cancer Study Group.
  • Of this patient population, 20 pretreatment biopsy specimens were available from the chemotherapy arm for immunohistochemical analysis of Factor VIII expression.
  • RESULTS: The patients who had a partial response (>50% decrease in tumor volume) or complete response to chemotherapy had a mean value of 20.90 (+/- 8.09 standard deviation [SD]) blood vessels per HPF.
  • Those who did not respond to chemotherapy and thus required a total laryngectomy had a mean value of 32.99 (+/- 10.10 SD) vessels per HPF.
  • Kaplan-Meier survival curve analysis also revealed that patients with vessel counts above the mean tended to have poorer survival than those below the mean regardless of treatment selection.
  • The most-vascular tumors, those greater than 1 SD above the mean, had a statistically significant difference in survival and laryngeal preservation (P = .0345).
  • CONCLUSIONS: These results indicate that tumor angiogenesis, as measured by number of vessels per HPF, was associated with decreased responsiveness to chemotherapy and radiation for larynx preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / blood supply. Laryngeal Neoplasms / blood supply. Laryngectomy. Neoadjuvant Therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Factor VIII / analysis. Female. Fluorouracil / administration & dosage. Humans. Larynx / pathology. Male. Microcirculation / drug effects. Microcirculation / pathology. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Salvage Therapy. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150616.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-27-8 / Factor VIII; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Ghaffar S, Akhtar S, Ikram M, Imam SZ, Sepah YJ: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak; 2010 Mar;20(3):171-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma.
  • OBJECTIVE: To compare outcome of patients with advanced laryngeal hypopharyngeal squamous cell carcinoma treated surgically or with chemotherapy and/or radiotherapy.
  • METHODOLOGY: Medical records of already treated stage-III and IV squamous cell carcinoma of larynx/hypopharynx patients were reviewed.
  • Group-A comprised of patients treated with surgery +/- adjuvant therapy whereas non-surgically managed patients were labeled as group-B.
  • Kaplan Meier technique was used to estimate mean recurrence time with standard errors.
  • RESULTS: Sixty two percent of group-A and 49% patients of group-B were stage-III.
  • In group-A, 40% patients received postoperative adjuvant therapy while in group-B, 45% received concomitant chemoradiation.
  • Mean recurrence time was 1369+193 days.
  • In group-A, mean recurrence time was 2097+277 days.
  • The hazard ratio of recurrence in hypopharyngeal tumours was 1.5 times (95% CI 0.68, 3.30) as compared to tumours of larynx.
  • The hazard ratio of recurrence was 1.98 times (95% CI 0.99, 3.95) when both larynx and hypopharynx were involved as compared to when tumour was localized to larynx only.
  • No residual disease was noted at the completion of treatment in surgical group-A while 62% patients of the group-B had residual disease at the completion of treatment.
  • Larynx was retained in only 25% patients in group-B.
  • CONCLUSION: Statistically significant difference was noted in disease free outcome when stage-III and IV larynx hypopharynx cancer was managed surgically as compared to non-surgical management.
  • Chances of retaining larynx are only 25% when managed non-surgically.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392379.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


57. Adham M, Baulieux J, Mornex F, de La Roche de Bransat E, Ducerf C, Souquet JC, Gerard JP: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer; 2000 Sep 1;89(5):946-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus.
  • BACKGROUND: Surgery remains the treatment of choice for patients with esophageal squamous cell carcinoma (SCC), but survival rates have not improved over the past decades.
  • The objective of this study was to evaluate the effect of multimodal therapy on resectability, on the overall and on disease free survival (DFS) rates, and on the laryngeal resection rate.
  • METHODS: Fifty-five patients (49 men and 6 women) with a mean age of 58 +/- 8 years underwent combined modality treatment for esophageal SCC.
  • The intent of combined therapy was curative in 87.3% of patients and palliative in 12.7% of patients.
  • Neoadjuvant treatment consisted of two courses of 5-fluorouracil and cisplatin on Days 1-5 and Days 21-25.
  • RESULTS: Full neoadjuvant treatment was possible in 67.3% of patients and was uneventful in 56.
  • The tumor stages according to the American Joint Committee on Cancer staging system were pT0N0 in 12 patients, Stage 0 in 8 patients, Stage IIa in 6 patients, Stage IIb in 6 patients, Stage III in 8 patients, and Stage IV in 13 patients.
  • Laryngeal preservation was achieved in 8 of 12 patients in whom total pharyngolaryngoesophagectomy initially was indicated because of tumor response and an R0 resection.
  • CONCLUSIONS: Neoadjuvant treatment is tolerated well by most patients.
  • Combination therapy increases the resectability rate and facilitates laryngeal preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Larynx / surgery. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Survival Rate. Treatment Outcome


58. Yoo SS, Carter D, Turner BC, Sasaki CT, Son YH, Wilson LD, Glazer PM, Haffty BG: Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer; 2000 Feb 20;90(1):22-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation.
  • The purpose of the current study is to evaluate the prognostic significance of cycD1 for local recurrence in early-stage larynx cancer treated with primary radiation therapy.
  • The study was conducted using a matched case-control design in 60 early-stage (T1-T2/N0) larynx cancer patients.
  • All patients had squamous cell carcinoma of the larynx and were treated with primary radiation to a total median dose of 66 Gy in daily fractions of 2 Gy, without surgery or chemotherapy.
  • Thirty patients who suffered a local relapse in the larynx after treatment served as the index case population.
  • These 30 cases were matched by age, sex, site (glottic vs. supraglottic), radiation therapy technique/dose, and follow-up, to 30 control patients who did not experience a local relapse.
  • Patients were considered to be positive for cyclin D1 if the staining was 2+ or greater with a percent distribution of at least 5%.
  • By design of the study, the two groups were evenly balanced with respect to age, sex, stage, radiation dose, and follow-up.
  • CycD1 levels correlated with proliferating cell nuclear antigen levels.
  • These data suggest that low levels of cycD1 correlate with relatively radioresistant early-stage larynx carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Cyclin D1 / analysis. Laryngeal Neoplasms / chemistry. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry
  • [MeSH-minor] Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Radiotherapy Dosage

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10725854.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


59. Kim JG, Sohn SK, Kim DH, Baek JH, Jeon SB, Chae YS, Lee KB, Park JS, Sohn JH, Kim JC, Park IK: Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer; 2005 Nov 14;93(10):1117-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
  • We aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  • In total, 37 patients with stage III or IV SCCHN were enrolled on the study.
  • The chemotherapy consisted of two cycles of intravenous cisplatin of 80 mg m(-2) on day 1 and oral capecitabine 825 mg m(-2) twice daily from day 1 to day 14 at 3-week intervals.
  • The radiotherapy (1.8-2.0 Gy 1 fraction day(-1) to a total dose of 70-70.2 Gy) was delivered to the primary tumour site and neck.
  • The primary tumour sites were as follows: oral cavity (n=6), oropharynx (n=11), hypopharynx (n=8), larynx (n=3), nasopharynx (n=6), and paranasal sinus (n=3).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Capecitabine. Disease Progression. Drug Therapy, Combination. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1472-81 [12237916.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1893-8 [12453857.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1115-20 [12853355.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3098-104 [12915600.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1578-86 [14504061.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):348-52 [14735175.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2648-53 [7989940.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):485-93 [10080589.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1350-7 [15684318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1961-9 [11283128.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2948-53 [10537364.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • (PMID = 16251869.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361495
  •  go-up   go-down


60. Rapoport A, Botelho RA, Souza RP, Cavalcanti SM, Furlam S, Tornin Ode S, Souza TR: The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. Braz J Otorhinolaryngol; 2008 Jan-Feb;74(1):74-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer.
  • The involvement of pre-epiglottis space can change the indication for partial laryngeal resection.
  • AIM: The aim of this study was to evaluate inter-observer and intra-observer agreement by means of computed tomography analysis regarding the involvement of the pre-epiglottis space (PES) from carcinoma of the upper aerodigestive tract and its relation with therapeutic planning.
  • MATERIALS AND METHODS: Retrospective study of ninety-five computed tomography exams of patients with squamous cell carcinoma, from 1990 to 2004, were selected and evaluated; 87 were males and eight females, with ages ranging from 32 to 73 years.
  • Imaging results were analyzed twice by three radiologists, individually, without any previous knowledge of the clinical stage.
  • No patient had received any previous treatment up to the moment of imaging examination, such as surgery, chemotherapy or radiotherapy.
  • CONCLUSIONS: After a general Kappa Index of 0.72, the results suggest a substantial agreement in the involvement of the PES by means of computed tomography analysis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Epiglottis / pathology. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Observer Variation. Reproducibility of Results. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392505.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


61. Vivek RS, Baludavid M, Mohanram R, Chitra, Amanullah, Vijayalakshmi, Bala, Kalaiyarasi, Saravanan: Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas. J Cancer Res Ther; 2006 Jul-Sep;2(3):90-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
  • PURPOSE: To investigate the feasibility of combining concomitant boost-accelerated radiation regimen (ACB) with full-dose mono-chemotherapy using cisplatin and to assess its local response and acute toxicity patterns in patients with advanced loco-regional head and neck squamous cell carcinoma (HNSCC).
  • MATERIALS AND METHODS: Between July 2004 and August 2005, a pilot study involving 27 patients with stage III to IVB (AJCC-6th) HNSCC of the oropharynx, hypopharynx and larynx who met the eligibility criteria was undertaken.
  • The radiation dose was 72 Gy in 42 fractions over 6 weeks, delivered in one daily fraction of 1.8 Gy during the first 3.5 weeks and two fractions per day, 1.8 Gy and 1.5 Gy boost-separated by > 6 h interval, during the last 2.5 weeks. cisplatin, 100 mg/m2, was given in intravenous (i.v.) infusion on day 1 and day 22.
  • RESULTS: Out of 27 patients, 24 patients received both radiation and chemotherapy as per protocol and were available for analysis.
  • CONCLUSION: This data shows that it is feasible to combine ACB and full-dose mono-chemotherapy using cisplatin with manageable, although substantial, toxicity.
  • The compliance to therapy was high and the loco-regional response achieved compared favorably with ACB alone or other concurrent chemoradiation regimens using standard or altered fractionation regimens tested by the Institute.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Patient Compliance. Pilot Projects


62. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB: T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. Am J Clin Oncol; 2007 Apr;30(2):181-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience.
  • PURPOSE: The purpose of this study was to report the outcomes after external-beam radiotherapy (RT) for selected T3 and T4 vocal cord squamous cell carcinomas.
  • METHODS AND MATERIALS: One hundred nine patients with previously untreated T3 and T4 squamous cell carcinomas of the glottic larynx were treated with curative intent in this Institutional Review Board-approved outcome study using continuous-course RT alone (106 patients) or followed by a planned neck dissection (3 patients) between September 1966 and June 2002.
  • Patients selected for such treatment had relatively low-volume, unilateral disease.
  • Patients were staged according to the recommendations of the American Joint Committee on Cancer (AJCC) as follows: T3N0, 68 patients (62%); T3N1, 14 patients (13%); T3N2B, 5 patients (5%); T4N0, 17 patients (16%); T4N1, 4 patients (4%); and T4N2B, 1 patient.
  • RESULTS: The 5-year outcomes after treatment were: local control for stage T3 and T4, 78% and 81%; locoregional control for AJCC stage III and IVa, 62% and 78%; distant metastasis-free survival for AJCC stage III and IVa, 97% and 100%; cause-specific survival for AJCC stage III and IVa, 84% and 87%; and overall survival for AJCC stage III and IVa, 52% and 67%, respectively.
  • Local control and ultimate cure probabilities will hopefully improve further with the addition of concomitant chemotherapy to RT for larger tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy. Vocal Cords

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414468.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Pradier O, Christiansen H, Schmidberger H, Martin A, Jäckel MC, Steiner W, Ambrosch P, Kahler E, Hess CF: Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1368-77
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck.
  • PURPOSE: To evaluate the efficacy of an adjuvant radiotherapy after transoral laser microsurgery for advanced squamous cell carcinoma of the head and neck and to show that a less invasive surgery with organ preservation in combination with radiotherapy is an alternative to a radical treatment.
  • PATIENTS AND METHODS: Between 1987 and 2000, 208 patients with advanced squamous cell carcinoma of the head and neck were treated with postoperative radiotherapy after surgical CO2 laser resection.
  • Primary sites included oral cavity, 38; oropharynx, 88; larynx, 36; hypopharynx, 46.
  • Disease stages were as follows: Stage III, 40 patients; Stage IV, 168 patients.
  • Before 1994, the treatment consisted of a split-course radiotherapy with carboplatinum (Treatment A).
  • After 1994, the patients received a conventional radiotherapy (Treatment B).
  • Patients treated with a hemoglobin level greater or equal to 13.5 g/dL before radiotherapy had a 5-year DSS of 55% as compared with 39% for patients treated with a hemoglobin level greater than 13.5 g/dL (p = 0.0054).
  • Treatment B has clearly been superior to Treatment A.
  • A further improvement of our treatment regimen might be expected by the combination of adjuvant radiotherapy with concomitant platinum-based chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery. Laser Therapy / methods. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hemoglobin A / analysis. Humans. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Mouth Neoplasms / radiotherapy. Mouth Neoplasms / surgery. Multivariate Analysis. Neoplasm Recurrence, Local. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):955; author reply 955-6 [16751078.001]
  • (PMID = 16169679.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9034-51-9 / Hemoglobin A
  •  go-up   go-down


64. Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E, Fu K: Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol; 2005 Mar 1;23(7):1447-54
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
  • PURPOSE: To determine the feasibility of high-dose intra-arterial (IA) cisplatin and concurrent radiation therapy (RT) for head and neck squamous cell carcinoma in the multi-institutional setting (Multi-RADPLAT).
  • PATIENTS AND METHODS: Eligibility included T4 squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.
  • Patients received cisplatin (150 mg/m(2) IA with sodium thiosulfate 9 g/m(2) intravenous [IV], followed by 12 g/m(2) IV over 6 hours, weekly for 4 weeks) and concurrent RT (70 Gy, 2.0 Gy/fraction, daily for 5 days over 7 weeks).
  • CONCLUSION: This intensive treatment regimen for head and neck cancer is feasible and effective in a multi-institutional setting.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Injections, Intra-Arterial. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735120.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-95-012
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Amdur RJ, Mendenhall WM, Stringer SP, Villaret DB, Cassisi NJ: Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus. Head Neck; 2001 May;23(5):353-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus.
  • PURPOSE: To report long-term results using radiotherapy with or without a planned neck dissection for T1-T2 carcinoma of the pyriform sinus.
  • Cause-specific survival rates at 5 years were as follows: stage I-II, 96%; stage III, 62%; stage IVA, 49%; and stage IVB, 33%.
  • The absolute survival rates were as follows: stage I, 57%; stage II, 61%; stage III, 41%; stage IVA, 29%; and stage IVB, 25%.
  • Moderate to severe long-term complications developed in 12% of patients.
  • CONCLUSIONS: RT alone or combined with a planned neck dissection resulted in local control with larynx preservation in a high proportion of patients.
  • The addition of adjuvant chemotherapy is unlikely to improve the probability of organ preservation, but might improve locoregional control for patients with advanced nodal disease.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Larynx / surgery. Neck Dissection. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Complications. Salvage Therapy. Time. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc.
  • (PMID = 11295808.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Worden FP, Moyer J, Lee JS, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Hogikyan N, Lassig AA, Emerick K, Mukherji S, Hadjiski L, Tsien CI, Miller TH, Wallace NE, Mason HL, Bradford CR, Wolf GT: Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope; 2009 Aug;119(8):1510-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
  • OBJECTIVES/HYPOTHESIS: High rates of overall survival (OS) and laryngeal preservation were achieved in two sequential phase II clinical trials in patients with stage III/IV laryngeal squamous cell carcinoma (SCC).
  • Patients were treated with chemoradiation after a >50% primary tumor response to one cycle of neoadjuvant chemotherapy (IC).
  • METHODS: Records from 36 patients with T4 SCC of the larynx with cartilage invasion alone (n = 16) or cartilage invasion and extralaryngeal spread (n = 20) were retrospectively reviewed.
  • Those achieving >50% response at the primary tumor received chemoradiation (70 Gy; 35 fractions with concurrent cisplatin-100 mg/m(2) [carboplatin (AUC 6)] every 21 days for 3 cycles), followed by adjuvant P+5FU for complete histologic responders (CHR).
  • Of these, 27 received definitive chemoradiation, 23 (85%) obtained CHR, with 58% laryngeal preservation rate.
  • Following chemoradiation, 8/11 (73%) patients with an intact larynx had >75% understandable speech, 6/36 (17%) were g-tube dependent and 6/36 (17%) were tracheostomy dependent.
  • CONCLUSIONS: Our results suggest that chemo-selection is a feasible organ preservation alternative to total laryngectomy for patients with T4 laryngeal SCC with cartilage invasion.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1478-85 [11720432.001]
  • [Cites] Head Neck. 2002 May;24(5):456-67 [12001076.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):467-72 [6486314.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):564-9 [2364368.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):559-68 [9635702.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):830-5 [16564646.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):655-61 [16785412.001]
  • [Cites] Curr Opin Oncol. 2007 May;19(3):188-94 [17414635.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 19504552.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-05; United States / NCI NIH HHS / CA / P50 CA97248; United States / NIDCD NIH HHS / DC / P30 DC 05188; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NIDCD NIH HHS / DC / DC005188-07; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NCI NIH HHS / CA / CA097248-05; United States / NIDCD NIH HHS / DC / P30 DC005188-07; United States / NIDCR NIH HHS / DE / DE013346-05; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS126278; NLM/ PMC2739984
  •  go-up   go-down


67. Sumitsawan Y, Chaiyasate S, Chitapanarux I, Anansuthiwara M, Roongrotwattanasiri K, Vaseenon V, Tooncam H: Late complications of radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx; 2009 Apr;36(2):205-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late complications of radiotherapy for nasopharyngeal carcinoma.
  • The mean pre- and post-treatment body mass indexes (BMI) were 22.5+/-4 (15-35.6), and 19.8+/-3.2 (12.9-34.5; P<0.05).
  • Most of the patients (92%) had undifferentiated (50.5%) and poorly differentiated (41.5%) squamous cell carcinoma.
  • Eighty-eight percent of the patients were in Stage III and IV.
  • Chemotherapy was given to 145 patients (72.5%).
  • The mean post-radiation period in the added chemotherapy group was lower than the group treated with radiation alone (2.9+/-2.7 years vs. 5.4+/-4.4 years, P<.05).
  • Added chemotherapy increased the complication severity significantly for the skin (P<0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Quality of Life. Radiotherapy Dosage. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635325.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


68. Corvò R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, Pallestrini E, Merlano M, Vitale V, Rosso R: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer; 2001 Dec 1;92(11):2856-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.
  • BACKGROUND: The authors previously have found that in patients with locally advanced squamous cell carcinoma of the head and neck (SCC-HN), alternating chemoradiotherapy (ALT) was superior to low-total-dose conventional radiotherapy alone.
  • METHODS: During 6 years, 136 consecutive patients with previously untreated unfavorable Stage II or Stage III-IV (International Union Against Cancer) SCC of the oral cavity, pharynx, and larynx were enrolled.
  • They were randomly assigned to chemotherapy consisting of 4 cycles of intravenous cisplatin (20 mg/m(2) of body surface area per day for 5 consecutive days) and 5-fluorouracil (200 mg/m(2) per day for 5 consecutive days; weeks 1, 4, 7, and 10) alternated with three 2-week courses of radiotherapy (20 grays [Gy] per course, 2 Gy per day, 5 days per week; ALT, 70 patients) or to partly accelerated radiotherapy with final concomitant boost technique (75 Gy/40 fractions in 6 weeks; partly accelerated radiotherapy [PA-RT], 66 patients).
  • RESULTS: At the median follow-up of 60 months (range, 30-102 months), no statistical differences were observed in overall survival, progression free survival, or locoregional control between the 2 treatments.
  • Therefore, definitive conclusions could not be made.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Second Primary / etiology. Patient Compliance. Regression Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11753959.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


69. Kotz T, Costello R, Li Y, Posner MR: Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck; 2004 Apr;26(4):365-72
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck.
  • METHODS: Twelve patients with stage III or IV squamous cell carcinoma of the head and neck were enrolled.
  • Postchemoradiation videofluorographic swallowing studies were performed from 1 to 14 weeks after the completion of treatment (mean, 8 weeks).
  • RESULTS: Changes in swallowing physiology after treatment included decreased base of tongue to posterior pharyngeal wall contact (p =.0010) and reduced pharyngeal contraction (p =.0313), resulting in impaired bolus transport through the pharynx.
  • In addition, decreased laryngeal elevation (p =.0039), decreased laryngeal vestibule closure (p =.0078), and laryngeal penetration (p =.0078) were present.
  • CONCLUSIONS: Organ preservation treatment impairs movement of structures essential for normal swallowing.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluoroscopy. Humans. Inhalation / physiology. Larynx / physiopathology. Male. Middle Aged. Pharynx / physiopathology. Radiotherapy / adverse effects. Sampling Studies. Video Recording


70. Prades JM, Schmitt TM, Timoshenko AP, Simon PG, de Cornulier J, Durand M, Guillot A, Martin C: Concomitant chemoradiotherapy in pyriform sinus carcinoma. Arch Otolaryngol Head Neck Surg; 2002 Apr;128(4):384-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemoradiotherapy in pyriform sinus carcinoma.
  • OBJECTIVES: To test the effectiveness of concurrent chemoradiotherapy in patients with pyriform sinus carcinoma and to demonstrate the feasibility of an organ preservation approach.
  • SETTING: University Hospital Center, St-Etienne, France.
  • PATIENTS: The study population comprised 46 male patients with resectable stage III and IV pyriform sinus carcinoma.
  • In protocol 1 (24 patients), carboplatin was given on days 1 through 5 and 28 through 33, with an area under the curve dose of 5 mg/mL for 1 minute per day and bifractionated radiotherapy (160 rad [1.6 Gy]/fraction) delivered on days 1 through 16 and 28 through 38.
  • A treatment break was planned on days 16 through 27.
  • In protocol 2 (22 patients), chemotherapy was given with the same dose of carboplatin on days 1 and 21, and fluorouracil (750 mg/m(2) per day) on days 1 through 7 and 21 through 28.
  • Radiotherapy with a single fraction of 180 rad (1.8 Gy)/d was delivered during the first 2 weeks and then 150 rad (1.5 Gy) twice a day during the next 3 weeks.
  • After 2 years of follow up, 16 patients (67%) (protocol 1) and 12 patients (55%) (protocol 2) retained their larynx without evidence of disease.
  • During therapy, 15 patients (63%) (protocol 1) and 19 patients (86%) (protocol 2) required unplanned hospitalization for toxic effects.
  • CONCLUSION: Concomitant chemotherapy and bifractionated radiotherapy, although toxic, leads to good locoregional control and therefore to a significant level of laryngeal preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy / adverse effects. Disease-Free Survival. Dose Fractionation. Fluorouracil / therapeutic use. Humans. Larynx. Male. Middle Aged. Survival Rate

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Otolaryngol Head Neck Surg. 2003 Dec;129(12):1351; author reply 1351 [14676171.001]
  • (PMID = 11926911.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Schweitzer VG: PHOTOFRIN-mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies. Lasers Surg Med; 2001;29(4):305-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PHOTOFRIN-mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies.
  • BACKGROUND AND OBJECTIVE: To determine the efficacy of PHOTOFRIN-mediated photodynamic therapy (PDT) for treatment of diffuse "field cancerization" of the oral cavity and Cis-T2N0M0 squamous cell carcinoma (SqCCa) of the larynx in patients not amenable or that have failed conventional head and neck treatment.
  • STUDY DESIGN/MATERIALS AND METHODS: Over the past 15 years 10 patients with early stage Tis-T2N0M0 SqCCa of the oral cavity and oropharynx and 10 patients with Tis-T2N0M0 SqCCa of the larynx were treated.
  • CRs (follow up 6 months-8 years) were achieved in eight of 10 patients with superficial laryngeal cancer obviating the need for total laryngectomy in previously treated radiation therapy patients.
  • CONCLUSION: PHOTOFRIN-mediated PDT provides a surgical oncologic modality for potentially curative treatment of early stage oral cavity and laryngeal malignancies with minimal side effects, absence of systemic toxicity, preservation of oral function and voice quality, with multiple drug administration, and laser light retreatment capability.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Dihematoporphyrin Ether / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Larynx / drug effects. Larynx / pathology. Larynx / radiation effects. Male. Middle Aged. Mouth / drug effects. Mouth / pathology. Mouth / radiation effects. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11746107.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


72. Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ, Stack BC Jr, Needles B, Boyd JH: Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999. Cancer; 2001 Mar 1;91(5):940-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
  • BACKGROUND: After standard therapy for advanced head and neck carcinoma, 5-year survival rate is less than 50%.
  • Our purpose was to develop a new treatment for advanced head and neck carcinoma by using preoperative chemotherapy.
  • METHODS: Between 1994 and 1999, 62 consecutive patients with newly diagnosed head and neck carcinoma were treated with paclitaxel and carboplatin induction chemotherapy.
  • Chemotherapy was administered every 21 days with 3 courses of paclitaxel (150-265 mg/m(2)) and carboplatin at a dose calculated using the Calvert formula area under the curve of 7.5.
  • Patients who achieved complete or partial response at the primary received definitive radiation to the primary tumor and those with lymph node disease received neck dissection followed by radiation to the regional lymph nodes.
  • Seventy-four percent had Stage IV (according to the 5th edition of American Joint Committee on Cancer Staging manual) disease.
  • The median duration of follow-up from initiation of chemotherapy was 64 weeks (range, 1-272 weeks).
  • Responses were observed at all anatomic sites: oropharynx 20 of 33 (61%); hypopharynx 8 of 12 (67%); and larynx 13 of 17 (76%).
  • Kaplan-Meier estimates of overall survival (OS), at 230 weeks, were significantly better in Stage IV oropharynx/hypopharynx responders than nonresponders (55% vs. 27%; P = 0.04).
  • Organ preservation was achieved in 28 of 62 (45%) of patients at all anatomic sites: oropharynx 39%, hypopharynx 42%, larynx 59%.
  • The response rate was encouraging considering most patients were Stage IV.
  • Chemotherapy response identified a group with improved prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11251945.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


73. Leethanakul C, Patel V, Gillespie J, Shillitoe E, Kellman RM, Ensley JF, Limwongse V, Emmert-Buck MR, Krizman DB, Gutkind JS: Gene expression profiles in squamous cell carcinomas of the oral cavity: use of laser capture microdissection for the construction and analysis of stage-specific cDNA libraries. Oral Oncol; 2000 Sep;36(5):474-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles in squamous cell carcinomas of the oral cavity: use of laser capture microdissection for the construction and analysis of stage-specific cDNA libraries.
  • Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer among men in the developed world affecting the oral cavity, salivary glands, larynx and pharynx.
  • Utilizing tissue from patients with HNSCC, we sought to systematically identify and catalog genes expressed in HNSCC progression.
  • Here, we demonstrate the successful use of laser capture microdissection for procuring pure populations of cells from patient tissue sets comprised of oral squamous cell carcinomas (OSCCs) and matching normal tissue.
  • The RNA was used for the synthesis of blunt-ended, double-strand complementary DNAs (cDNAs) by oligo (dT)-mediated reverse transcription, followed by addition of linkers.
  • These results demonstrate that high quality, representative cDNA libraries can be generated from microdissected OSCC tissue.
  • Furthermore, these finding suggest the existence of at least 132 novel genes expressed in our cDNA libraries, which may have a role in the pathogenesis of HNSCC, and may represent novel markers for early detection as well as targets for pharmacological intervention in this disease.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA, Complementary / genetics. Dissection / methods. Gene Expression Profiling / methods. Gene Library. Lasers. Mouth Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10964057.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Neoplasm
  •  go-up   go-down


74. Taguchi T, Tsukuda M, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Nishimura G, Nagao J: Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Auris Nasus Larynx; 2009 Apr;36(2):199-204
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
  • OBJECTIVE: To review our experience in the treatment of concurrent chemoradiotherapy (CCR) for patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and to evaluate the different factors affecting survival and primary organ preservation.
  • Of 101 patients, 76 were treated with a cisplatin, 5-fluorouracil, methotrexate, and leucovorin (PFML) regimen and 25 were treated with a carboplatin and uracil-tegafur (CBDCA-UFT) regimen.
  • On multivariate analysis, resectability of the tumor and degree of histological differentiation were significant predictors of survival for patients undergoing CCR; T stage and differentiation were significant prognostic factors for primary organ preservation.
  • CONCLUSION: In the treatment of CCR for advanced SCCHN, the survival rate of the patients with resectable tumors was excellent and significantly greater compared with the patients with unresectable tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Otorhinolaryngologic Neoplasms / drug therapy. Otorhinolaryngologic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632233.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Kornek GV, Selzer E: [Organ sparing treatment modalities - which type of treatment for which carcinoma?]. Wien Med Wochenschr; 2008;158(9-10):264-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ sparing treatment modalities - which type of treatment for which carcinoma?].
  • [Transliterated title] Organerhaltende Therapiemodalitäten - welche Therapie für welches Karzinom?
  • Radical surgery followed by postoperative radiotherapy is still the most effective treatment option for advanced resectable head and neck cancer.
  • It is therefore of utmost importance to determine the resectability before start of the treatment.
  • For those patients who suffer from unresectable cancer or refuse to undergo surgery, alternatives, such as induction-chemotherapy or radiotherapy plus chemotherapy alone may be offered.
  • Historical studies investigating alternative treatment protocols were conducted almost 20 years ago.
  • These studies demonstrated that in approximately 2/3 of all patients with laryngeal and hypopharyngeal cancer undergoing induction-chemotherapy according to the PF-protocol (cisplatin plus 5-FU as a continuous infusion) and subsequent radiotherapy, larynx preservation without negative impact on overall survival could be achieved.
  • At least three randomized studies have shown a clinical advantage for a treatment combination consisting of docetaxel or paclitaxel plus CDDP/5-FU over a historical control regimen containing CDDP/5-FU alone.
  • This novel combination therefore is currently regarded as the gold-standard for induction-chemotherapy in advanced head and neck cancer patients.
  • A further significant addition to the therapeutic armamentarium for the head and neck radiation oncologist is the recently introduced monoclonal antibody cetuximab.
  • It was found in a randomized landmark study that addition of cetuximab to radiotherapy significantly improves local control as well as overall survival of advanced stage head and neck cancer patients.
  • In light of these recent developments this review discusses the role of organ sparing treatment protocols and different levels of evidence with special consideration of tumor localization.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Invasiveness. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Randomized Controlled Trials as Topic. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 1998 Oct;8(4):262-9 [9873104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • (PMID = 18560952.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 17
  •  go-up   go-down


76. Schwartz DL, Montgomery RB, Yueh B, Donahue M, Anzai Y, Canby R, Buelna R, Anderson L, Boyd C, Hutson J, Keegan K: Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer; 2005 Jun 15;103(12):2534-43
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
  • BACKGROUND: The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB-XRT) for locally advanced head and neck squamous cell carcinoma.
  • METHODS: Twenty patients with Stage III or IV (M0) disease of the oropharynx, supraglottic larynx, or hypopharynx were enrolled.
  • Patients with stable (SD) or responding disease subsequently received dose-escalated docetaxel (10-20 mg/m2 in sequential patient cohorts) and carboplatin AUC 1 weekly x 5 with CB-XRT (1.8 gray [Gy] every day x 15 days, followed by 1.8/1.5 Gy twice per day x 13 days).
  • RESULTS: All patients were evaluable, and 15 patients (5 patients with Stage III disease, 10 patients with Stage IV disease) completed all planned therapy.
  • Thirteen patients remain free of any disease event, with a median follow-up of 15 months (range, 3-29 months).
  • Early Phase II outcomes revealed promising activity in patients completing all treatment.
  • Initial induction response results suggested that further investigation of this regimen with more aggressive induction therapy is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15856475.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


77. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • Multivariate analysis of the overall population revealed that the only parameter that was significantly related to the probability of local control after RT was T stage.
  • CONCLUSIONS: The most important parameter that has an impact on local control after RT is T stage.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


78. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol; 2010 Jun 20;28(18):2989-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
  • PATIENTS AND METHODS: Patients with previously untreated stage III or IV (excluding T1-2N1 and M1) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx were randomly assigned to receive definitive radiotherapy (70 Gy in 7 weeks) concurrently with either CIS (100 mg/m(2)) on day 1 of weeks 1, 4, and 7 or CIS (75 mg/m(2)) plus TPZ (290 mg/m(2)/d) on day 1 of weeks 1, 4, and 7 and TPZ alone (160 mg/m(2)/d) on days 1, 3, and 5 of weeks 2 and 3 (TPZ/CIS).
  • There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. International Agencies. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Quality of Life. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Triazines / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jun 20;28(18):2941-3 [20479396.001]
  • [ErratumIn] J Clin Oncol. 2014 May 1;32(13):1386
  • (PMID = 20479425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triazines; 1UD32YR59G / tirapazamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


79. Nishimura G, Tsukuda M, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Kawakami M, Watanabe M, Niho T, Abo H, Yamomoto S: Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation. Anticancer Res; 2009 Feb;29(2):661-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation.
  • BACKGROUND: Although the survival rate of early-stage laryngeal squamous cell carcinoma (SCC) patients treated by radiotherapy (RT) is sufficient, the larynx preservation rate is unsatisfactory.
  • To improve the larynx preservation rate, such patients have been treated by RT with chemotherapeutic agents.
  • There were no significant differences in the response and survival rates between the treatment methods both in T1 and T2 cases.
  • The 5-year larynx preservation survival rate was improved significantly by CCRT in T2 cases (66.7% vs. 93.3%; p < 0.01).
  • CONCLUSION: CCRT for early-stage laryngeal SCC patients was efficacious to improve the larynx preservation survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tegafur / administration & dosage. Tegafur / adverse effects. Thyroid Gland / drug effects. Thyroid Gland / radiation effects. Uracil / administration & dosage. Uracil / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331217.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin; 1-UFT protocol
  •  go-up   go-down


80. Benasso M, Vigo V, Bacigalupo A, Ponzanelli A, Marcenaro M, Corvò R, Margarino G: A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck. Radiother Oncol; 2008 Oct;89(1):44-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
  • BACKGROUND: The addition of gemcitabine may be a reasonable way to enhance the activity of the alternating cisplatin/5-fluorouracil and radiation regimen considered the referring approach for patients with advanced squamous cell carcinoma (SCC) of the head and neck at the National Institute for Cancer Research of Genoa.
  • METHODS: Three courses of cisplatin, 20mg/m(2)/day and 5-fluorouracil, 200mg/m(2)/day, days 1-5 (weeks 1, 4, and 7) alternated to 3 courses of radiotherapy at standard fractionation (weeks 2-3, 5-6, 8-9) up to 60Gy, and gemcitabine, 50mg/m(2) on monday of each week of radiation, were administered to 47 patients with stage IV (42 patients) or relapsed after surgery (5 patients), SCC of the oral cavity, pharynx or larynx.
  • RESULTS: Eighty-five percent of the patients completed the planned treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423671.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R: The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol; 2004 Dec;31(6 Suppl 18):2-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
  • Concurrent chemotherapy and radiation has improved the outcome for patients presenting with locally advanced squamous cell carcinomas of the head and neck (SCCHN).
  • These improvements have come at a cost of increased treatment-related toxicities.
  • We previously reported the results of a phase II trial examining the role of concurrent carboplatin, paclitaxel, and daily radiotherapy (RT) in SCCHN.
  • From April 2002 to September 2004, 19 patients with stage III-IV SCCHN were enrolled on a prospective phase II trial.
  • Treatment consisted of daily RT delivered to 70.2 Gy (1.8 Gy/fx) with amifostine 500 mg IV (<1 hour before RT), and concurrent weekly carboplatin (100 mg/m2) and paclitaxel (40 mg/m2).
  • Tumor characteristics based on histology were: primary cancers of the oropharynx (55.6%); supraglottic larynx (16.7%); hypopharynx (16.7%); oral cavity (5.6%); and unknown primaries (5.6%).
  • Toxicities were measured weekly during treatment and at each follow-up visit.
  • Disease response to therapy was determined 2 months after completion of therapy.
  • Eighty-four percent completed the prescribed radiation treatment, and 84% of patients received more than six cycles of chemotherapy.
  • The median number of missed chemotherapy cycles was 1.5 (range, 0 to 5 cycles).
  • Grade 3 toxicities associated with therapy were: mucositis and dysphagia (40% of patients each), dehydration (27%), xerostomia (20%), and dermatitis (20%); 53% of patients experienced grade 3 leukopenia, while grade 3/4 neutropenia developed in 20%/13%.
  • Forty percent of patients completed RT without unscheduled treatment breaks secondary to treatment-related toxicity.
  • Median treatment-break time was 5 days (range, 0 to 20 days).
  • Weekly carboplatin and paclitaxel administered concurrently with definitive RT and daily amifostine is well tolerated, with over 85% of patients completing therapy with acceptable toxicity.
  • The addition of amifostine appears to decrease treatment-related toxicity without impacting efficacy.
  • [MeSH-major] Amifostine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / adverse effects. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mucous Membrane / drug effects. Paclitaxel / adverse effects
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726515.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


82. Airoldi M, Cattel L, Cortesina G, Giordano C, Pedani F, Recalenda V, Danova M, Gabriele AM, Tagini V, Porta C, Bumma C: Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol; 2004 Apr;27(2):155-63
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study.
  • Concomitant chemoradiotherapy is the most effective treatment of unresectable head and neck cancer.
  • Docetaxel and carboplatin are two active drugs that potentiate radiotherapy.
  • Thirty patients (median age = 56 years; median Eastern Cooperative Oncology Group performance status = 1) received radiotherapy (70 Gy, 2 Gy/d, 5 d/wk) concurrent with carboplatin AUC 0.3 to 0.5 on day 1-5, weeks 1, 3, 5, 7, and docetaxel 15 to 25 mg/m2 on day 4 of weeks 2, 4, and 6.
  • Site of unresectable squamous cell carcinoma was as follows: oropharynx, 41%; hypopharynx, 27%; oral cavity, 16%; and larynx, 16%.
  • Stage was III in 13% and IV in 87%.
  • Median radiotherapy dose was 69 Gy, and 175 out of 210 courses (83%) were administered.
  • At the end of the treatment, we had 20 complete responses (CR) (67%), 9 partial responses (30%), and 1 no change (3%).
  • Carboplatin, docetaxel, and concomitant conventional radiotherapy is a feasible and effective treatment of unresectable head and neck cancer.
  • The concurrent administration of two drugs does not alter pharmacokinetic drug behavior compared with single-agent data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Area Under Curve. Carboplatin / administration & dosage. Carboplatin / pharmacokinetics. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Survival Analysis. Taxoids / administration & dosage. Taxoids / pharmacokinetics. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15057155.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


83. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Müser M, Knecht R: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol; 2001 Jun;47(6):519-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx.
  • In this open uncontrolled phase I study, nine patients with stage III and IV squamous cell carcinoma of the head and neck (SCCHN) were treated with five administrations of the humanized antiepidermal growth factor receptor monoclonal antibody EMD 72000 in three consecutive ascending dose groups.
  • The most frequent study drug-related AEs were fever and a transient elevation of liver enzymes.
  • In all patients, the time to reach peak serum concentrations (tmax) was within 1-3 h of the start of each EMD 72000 infusion.
  • In conclusion, EMD 72000 was very well tolerated in patients with advanced stage SCCHN.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Carcinoma, Squamous Cell / therapy. Hypopharynx. Laryngeal Neoplasms / therapy. Pharyngeal Neoplasms / therapy. Receptor, Epidermal Growth Factor / immunology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11459205.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


84. Shimane T, Mori T, Ono T, Monden T, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1141-4
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
  • Palliative treatments are applied for older adult cases that are not indicated for either surgery or potential chemotherapy, as well as in cases with unresectable primary lesions, distant metastases, and serious complications among head and neck cancer cases.
  • There is no established treatment for such cases, and therefore treatment has to be selected on a case-by-case basis.
  • Two cases showing sustained QOL after long administration of S-1 are presented in this paper.
  • The first is an 84-year-old male patient with cancer of the hypopharynx (T3N2aM1, stage IVc).
  • The second is a 70- year-old male patient who had recurrent cancer of the larynx (T1N0M0, stage I) after primary treatment.
  • Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Humans. Male. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620804.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


85. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope; 2009 Aug;119(8):1518-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 variant isoforms in head and neck squamous cell carcinoma progression.
  • The objective of this study was to investigate the role of the CD44 v3, v6, and v10 variant isoforms in head and neck squamous cell carcinoma (HNSCC) tumor progression behaviors.
  • STUDY DESIGN: Laboratory study involving cell cultures and clinical tissue specimens.
  • METHODS: Analysis of the expression of standard CD44s and the CD44 variant isoforms v3, v6, and v10 was carried out in the HNSCC cell line, HSC-3.
  • Immunohistochemical analysis was performed on clinical tissue specimens obtained from a series of 82 HNSCC patients.
  • The expression of standard CD44s and the CD44 v3, v6, and v10 variants in primary tumor specimens (n = 82) and metastatic cervical lymph nodes (n = 24) were analyzed with respect to various clinicopathologic variables.
  • Compared with primary tumors, a greater proportion of metastatic lymph nodes demonstrated strong expression of CD44 v3 (lymph node 14/24 vs. primary tumor 38/82), CD44 v6 (lymph node 18/24 vs. primary tumor 26/82), and CD44 v10 (lymph node 14/24 vs. primary tumor 16/82), while expression of standard CD44 was not significantly different in metastatic lymph nodes and primary tumors (lymph node 10/24 vs. primary tumor 60/82).
  • Expression of CD44 variant isoforms were associated with advanced T stage (v3 and v6), regional (v3) and distant (v10) metastasis, perineural invasion (v6), and radiation failure (v10).
  • CD44 v6 and CD44 v10 were also significantly associated with shorter disease-free survival.
  • Furthermore, expression of certain CD44 variants may be important molecular markers for HNSCC progression and should be investigated as potential therapeutic targets for therapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 Mar;85(4):514-8 [10691836.001]
  • [Cites] Semin Cancer Biol. 2008 Aug;18(4):251-9 [18450475.001]
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):410-5 [10804289.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1088-95 [11014576.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1217-23 [11031408.001]
  • [Cites] Tumour Biol. 2001 Jan-Feb;22(1):45-53 [11054026.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):115-20 [11223837.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32 [11283501.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5275-83 [11431370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):628-35 [11764382.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4067-72 [11751503.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48679-92 [11606575.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] J Lab Clin Med. 2002 Jan;139(1):59-65 [11873246.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2059-64 [12209509.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):745-7 [12213700.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25285-8 [12738783.001]
  • [Cites] Auris Nasus Larynx. 2004 Mar;31(1):35-41 [15041052.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):102-18 [15051494.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26991-7007 [15090545.001]
  • [Cites] Exp Mol Pathol. 2004 Aug;77(1):18-25 [15215046.001]
  • [Cites] Front Biosci. 1998 Jul 1;3:d637-49 [9634539.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):443-55 [8426113.001]
  • [Cites] J Cell Physiol. 1995 Jan;162(1):127-33 [7529235.001]
  • [Cites] J Pathol. 1996 May;179(1):66-73 [8691348.001]
  • [Cites] J Cell Physiol. 1997 May;171(2):152-60 [9130462.001]
  • [Cites] J Cell Physiol. 1998 Jul;176(1):206-15 [9618160.001]
  • [Cites] Front Biosci. 1999 Jan 1;4:A1-8 [9872731.001]
  • [Cites] Cell Motil Cytoskeleton. 1999;43(4):269-87 [10423269.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):837-45 [10446451.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):19-24 [16415424.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14026-40 [16565089.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1356-65 [16557236.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):771-8 [16847188.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1163-8 [16855392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):281-8 [17372087.001]
  • [Cites] Head Neck. 2007 Jun;29(6):550-8 [17252589.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] J Cell Physiol. 2000 May;183(2):182-95 [10737894.001]
  • (PMID = 19507218.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA066163-14; United States / NCI NIH HHS / CA / R01 CA078633-10; United States / NIAMS NIH HHS / AR / P01 AR039448-190007; United States / NCI NIH HHS / CA / CA078633-10; United States / NCI NIH HHS / CA / R01 CA066163-14; United States / NCI NIH HHS / CA / R01 CA66163; United States / NIAMS NIH HHS / AR / P01 AR039448; United States / NCI NIH HHS / CA / R01 CA078633; United States / NIAMS NIH HHS / AR / AR039448-190007; United States / NIAMS NIH HHS / AR / P01 AR39448; United States / NCI NIH HHS / CA / R01 CA066163
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS113866; NLM/ PMC2718060
  •  go-up   go-down


86. Corvò R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol; 2007 Oct;85(1):156-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based radiation oncology in head and neck squamous cell carcinoma.
  • BACKGROUND AND PURPOSE: Historically, radiation therapy (RT) has been an available treatment option for patients with early resectable head and neck squamous cell carcinoma (HNSCC) and the sole therapy for those with unresectable or inoperable disease.
  • Recently, four noteworthy strategies have emerged for the improvement of therapeutic outcome in the curative treatment of HNSCC: they include the development of altered fractionation radiotherapy, integration of chemotherapy with radiotherapy, incorporation of intensity-modulated radiotherapy and the introduction of targeted biological therapy.
  • These strategies are briefly reviewed in an effort to help interpret evidence-based data and to facilitate clinical-decision making in a clinical context.
  • MATERIALS AND METHODS: For patients with early stage HNSCC no level 1 study exists in which radiation therapy is compared with conservative surgery for the evaluation of local control or survival.
  • For patients with locally advanced HNSCC the recommendations to address the questions about better treatment in resectable and unresectable tumors are based on more than 100 randomized Phase III trials included in six meta-analyses on chemo-radiotherapy and/or altered fractionation.
  • RESULTS: External radiotherapy and/or brachytherapy are crucial treatment options in patients with early stage HNSCC.
  • For patients with locally advanced HNSCC, where outcome with conventional radiotherapy is poor, meta-analyses and collective data showed that loco-regional control may be improved at high level of evidence by altered fractionation radiotherapy, chemo-radiotherapy with concomitant approach or association of selected hypoxic cell radiosensitizer with radiotherapy.
  • Chemo-radiotherapy programs can achieve an improved larynx-function preservation program without the risk of overall survival reduction, for patients with larynx or hypopharynx tumors who are candidates to radical surgery followed by radiotherapy.
  • Despite improved results, a higher severe toxicity has been largely evidenced with concomitant chemo-radiotherapy by reducing the gain in the therapeutic index with new treatment strategies.
  • CONCLUSIONS: Stepwise improvements in HNSCC non-surgical therapy have shown favorable impact on loco-regional control and overall survival.
  • However, despite hundreds of clinical trials in patients with advanced disease, there is no absolute consensus about patient selection for altered fractionation regimens, type of chemo-radiotherapy association, radiation or chemotherapy dose schedule.
  • Nevertheless, many well-conducted clinical studies have expanded therapy options besides standard radiotherapy and have contributed to defining the evolving standard of care for patients with HNSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Evidence-Based Medicine. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Dose Fractionation. Humans. Nimorazole / therapeutic use. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482300.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 469ULX0H4G / Nimorazole
  • [Number-of-references] 103
  •  go-up   go-down


87. Yoon TM, Lee JK, Cho JS, Lim SC, Chung WK: Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer. J Otolaryngol Head Neck Surg; 2010 Apr;39(2):142-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer.
  • OBJECTIVES: The efficacy and toxicity of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy or radiotherapy only and their impact on laryngeal preservation and survival were studied in patients with supraglottic cancer.
  • METHODS: Forty-four patients with newly diagnosed supraglottic squamous cell carcinoma (stage II, III, IV) were treated with either two to three cycles of neoadjuvant chemotherapy with cisplatin 100 mg/m2 on day 1 and fluorouracil 800 to 1000 mg/m2 on days 1 to 5, followed by radiotherapy (NC + RT group, from March 1995 to December 1999; median 68.7 Gy, 1.8 to 2 Gy per fraction) or concurrent chemoradiotherapy (NC + CCRT group, from January 2000 to February 2003; radiotherapy concurrently with cisplatin 60 to 80 mg/m2 on day 1 and fluorouracil 600 to 800 mg/m2 on days 1 to 5).
  • Age, nodal stage, and tumour response after neoadjuvant chemotherapy were significant prognostic factors for OS and DSS (p < .05).
  • The 5-year disease-specific survival rates with larynx preservation were 42% in the NC + RT group and 73% in the NC + CCRT group (p = .028).
  • CONCLUSIONS: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with cisplatin and fluorouracil was effective as primary therapy for supraglottic cancer with laryngeal preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Supraglottic laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211100.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Burian M: [Recommendation for guidelines in the treatment of squamous cell cancer of the upper aerodigestive tract]. Wien Med Wochenschr; 2008;158(9-10):283-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recommendation for guidelines in the treatment of squamous cell cancer of the upper aerodigestive tract].
  • [Transliterated title] Ein Vorschlag für Leitlinien der Behandlung von Plattenepithelkarzinomen des oberen Aerodigestivtraktes.
  • If we look at the historical development of the treatment of head and neck cancer, we can see that initially, decisions about therapy lay solely in the hands of the surgeons (Otorhinolaryngologists, oral and maxilla-facial surgeons) This was also true of the decision as to whether an operation was feasible or whether primary radio therapy was to be carried out.
  • At the end of the last century, after chemotherapy had become an integral part of curative therapy, inter-disciplinary conferences (tumour boards) were set up so that the surgeons could make joint decisions about therapy together with radio oncologists and medical oncologists.
  • In addition, the increasingly important role of chemotherapy in curative therapy in the last fifteen years has led to a marked increase in the number of clinical studies in head and neck cancer.
  • Inter-disciplinary treatment decisions can be based only on current scientific knowledge and are geared towards a standard treatment as recommended for an individual tumour stage.
  • It is precisely in the upper aerodigestive tract that there are various therapeutical procedures, due to the different site of primaries (oral cavity, oro-, hypoparynx and larynx) and the different grade of locoregional metastasis.
  • One possible way to assure a high degree of transparency of these various therapies and making them available to a high number of colleagues is the development guidelines [1].
  • Many medical associations and organisations in Austria are currently engaged in the formulation and definition of guidelines, in order to provide the highest possible quality of medical treatment and care for each individual patient.
  • By guidelines are meant recommendations for treatments which allow a certain amount of flexibility in the treatment and provide a medical consensus in line with current scientific knowledge.
  • The following proposal is designed to provide a basis for the formulation of guidelines for the treatment of head and neck cancer in Austria.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Otorhinolaryngologic Neoplasms / therapy. Practice Guidelines as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560956.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


89. Portaluri M, Fucilli FI, Castagna R, Bambace S, Pili G, Tramacere F, Russo D, Francavilla MC: Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation. Int J Radiat Oncol Biol Phys; 2006 Nov 15;66(4):1036-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.
  • PURPOSE: To evaluate the dosimetric parameters of three-dimensional conformal radiotherapy (3D-CRT) in locally advanced head-and-neck tumors (Stage II and above) and the effects on xerostomia.
  • METHODS AND MATERIALS: A total of 49 patients with histologically proven squamous cell cancer of the head and neck were consecutively treated with 3D-CRT using a one-point setup technique; 17 had larynx cancer, 12 oropharynx, 12 oral cavity, and 6 nasopharynx cancer; 2 had other sites of cancer.
  • Of the 49 patients, 41 received postoperative RT and 8 definitive treatment.
  • Also, 13 were treated with cisplatin-based chemotherapy before and during RT; in 6 cases, 5-fluorouracil was added.
  • The follow-up time was 484-567 days (median, 530 days).
  • The mean dose to the primary planning target volume was 49.54 +/- 4.82 Gy (51.53 +/- 5.47 Gy for larynx cases).
  • The average dose to the contralateral parotid gland was approximately 38 Gy (30 Gy for larynx cases).
  • The maximal dose to the spinal cord was 46 Gy.
  • A Grade 0 Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer xerostomia score corresponded to a mean dose of 30 Gy to one parotid gland.
  • A lower xerostomia score with a lower mean parotid dose and longer follow-up seemed to give rise to a sort of functional recovery phenomenon.
  • With a mean dose of approximately 30 Gy to the contralateral parotid, we observed no or mild xerostomia.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiometry / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Burden. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Relative Biological Effectiveness. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750321.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Homma A, Shirato H, Furuta Y, Nishioka T, Oridate N, Tsuchiya K, Nagahashi T, Aoyama H, Inuyama Y, Fukuda S: Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J; 2004 Sep-Oct;10(5):326-32
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.
  • PURPOSE: This randomized, phase II study aimed to compare concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin as a treatment for squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: One hundred nineteen patients with moderate- to advanced-stage disease were eligible for the study.
  • Fifty-three patients had stage II disease, 28 had stage III, and the remaining 38 had stage IV disease.
  • Primary tumor sites included the larynx (N = 63), oropharynx (N = 30), hypopharynx (N = 23), and oral cavity (N = 3).
  • The radiotherapy dose of 65 Gy was given in 26 fractions over 45 days, dependent on a good tumor response at 40 Gy.
  • RESULTS: The median follow-up time was 63 months.
  • The 5-year overall survival rate did not significantly differ between treatments: 71.4% for carboplatin and 66.0% for cisplatin.
  • DISCUSSION: These findings suggest that weekly carboplatin treatment is preferable to daily low-dose cisplatin.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15530262.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Kubota A, Furukawa M, Komatsu M: [Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy]. Nihon Jibiinkoka Gakkai Kaiho; 2004 Nov;107(11):1004-10
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy].
  • Subjects were 15 patients--13 men and 2 women--with squamous cell carcinoma of the head and neck, indicating total laryngectomy.
  • Three had stage III disease and 12 stage IV disease.
  • These patients were treated with concurrent chemoradiotherapy and had been followed up for more than 2 years from the start of treatment.
  • Primary sites were hypopharynx in 7, larynx in 6, or oropharynx in 2.
  • Treatment consisted of 5-Fluorouracil (5-FU) on cis-platinum (CDDP).
  • 5-FU was given at 1000 mg/m2 per day as continuous infusions during 4 days, and 60 mg/m2 of CDDP was given on day 4 beginning on day 1 and 35 of a concurrent chemoradiotherapy course.
  • Radiation was given in single daily fractions of 2 Gy and 5 fractions per week to a total dose of 60 to 70 Gy.
  • The median total delivered dose of radiation was 66 Gy.
  • Twelve PT (80%) received scheduled treatment.
  • The larynx was preserved and free of disease in 60% of patients overall.
  • Failure patterns showed 5 with locoregional recurrence and 1 with distant metastasis.
  • Concurrent chemoradiotherapy improved two-year OS and PFS compared to radiotherapy alone with a significant difference.
  • Concurrent chemoradiotherapy is thus effective in preserving the larynx in a high percentage of patients and improving two-year OS and PFS rates without compromising QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Quality of Life. Radiotherapy Dosage. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624506.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx].
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • The distribution of the patients according to UICC in 1997 was as follows: stage I 4, stage II 15, stage III 18, stage IV 30.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • CONCLUSIONS: Poorly differentiated carcinomas of the supraglottic larynx had characteristics of the advanced stage in terms of earlier lymph node metastasis and a relatively high rate of cervical and distant metastasis.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • For patients with T3 who need partial laryngectomy and patients with advanced N stage, the combination of surgery with radiotherapy was supposed to be a priority.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Altumbabić H, Salkić A, Ramas A, Burgić M, Kasumović M, Brkić F: Pattern of head and neck malignant tumours in a Tuzla ENT clinic--a five year experience. Bosn J Basic Med Sci; 2008 Nov;8(4):377-80
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One overriding factor in deciding on treatment policy is the tendency for head and neck malignancy to be limited to the primary site and regional lymph nodes with surgery and chemotherapy and radiotherapy.
  • The most common sites for head and neck malignancies were found to be in the larynx (26,1%), oral cavity (21,7%), the thyroid gland (14,64 %) and the neck (8,51%).
  • A total of 230 patients were diagnosed with laryngeal carcinoma (M:173; F:57), showing the increasing number of female patients.
  • The histopathological tumour types found in this work were mostly squamous cell carcinoma (72,09%), papillary carcinoma (12,2%), while many other minor histopathological variants accounted for 13%.
  • The most patients were presented with stage I and stage III of disease (27% and 28,3%), and 19,9% with stage IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125712.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


94. Allal AS, Taussky D, Mach N, Becker M, Bieri S, Dulguerov P: Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys; 2004 Apr 1;58(5):1431-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
  • The therapeutic ratio may be particularly favorable for 5-week regimens.
  • This study reports the 10-year experience of a single institution in the routine use of concomitant boost RT as standard radical treatment in all but the most favorable stage patients.
  • METHODS AND MATERIALS: Between February 1991 and June 2001, 296 patients (mean age, 59 years) were treated with concomitant boost RT either alone (67%) or combined with cisplatin-based chemotherapy (33%), with a median tumor dose of 69.9 Gy.
  • Tumors were located in the oropharynx in 52%, hypopharynx in 20%, larynx in 15%, nasopharynx in 7%, and oral cavity in 6%.
  • International Union Against Cancer Stage III-IV disease represented 77% of tumors.
  • Twenty patients (7%) had a treatment interruption (median, 5 days; range, 2-35 days).
  • Grade 3-4 Radiation Therapy Oncology Group acute toxicity was observed in 77% of patients, and nutritional support was required in 110 patients (37%).
  • In a multivariate analysis, only T and N stage was significantly associated with locoregional control and disease-free survival.
  • Concomitant chemotherapy administration is feasible provided that patients are carefully selected and supportive care is introduced in a timely fashion.
  • Considering the manageable toxicity and the satisfactory tumor control obtained, this regimen represents a good choice when considering implementation of an altered RT fractionation schedule as standard treatment for head-and-neck cancers.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050320.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


95. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, Kowalski LP: Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1317-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only patients with recurrent head and neck squamous cell carcinoma undergoing en bloc salvage resection were eligible for the study.
  • RESULTS: The tumor location was the lip in 6 patients, oral cavity in 55, oropharynx in 31, larynx in 24, and hypopharynx in 8.
  • Previous treatment was surgery alone in 20 patients, radiotherapy alone in 68, surgery and radiotherapy in 21, and radiotherapy and chemotherapy in 14.
  • An additional patient received chemotherapy alone before salvage surgery.
  • The clinical stage of the recurrent tumor was I or II in 23 patients and III or IV in 101 patients.
  • The major factor associated with the overall occurrence of postoperative complications was the clinical stage of the recurrent tumor (P =.02).
  • The occurrence of minor complications correlated with the previously treated site, with complications occurring more often in patients undergoing locoregional vs local treatment (P =.04).
  • Major complications were associated with the time between initial treatment and salvage surgery (P =.05).
  • The clinical stage of the recurrent tumor and the previous site treated were the 2 major factors associated with the occurrence of postoperative complications.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Morbidity. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676158.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Teknos TN, Myers LL, Bradford CR, Chepeha DB: Free tissue reconstruction of the hypopharynx after organ preservation therapy: analysis of wound complications. Laryngoscope; 2001 Jul;111(7):1192-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free tissue reconstruction of the hypopharynx after organ preservation therapy: analysis of wound complications.
  • PURPOSE: Previous series have demonstrated a 77% rate of major wound complications in salvage surgery of the larynx following organ preservation protocols.
  • The purpose of this study is to determine the incidence of wound complications in these patients when microvascular free tissue transfers are used for reconstruction of the hypopharynx.
  • PATIENTS AND METHOD: We reviewed the medical records of 42 patients with stage III and IV laryngeal squamous cell carcinoma treated with an organ-sparing protocol consisting of induction chemotherapy followed by definitive radiation therapy.
  • Ten of these patients who required surgical salvage were reconstructed using radial forearm free tissue or lateral arm transfer and constitute the study group.
  • One patient in this study group had a small pharyngocutaneous fistula that resolved with conservative therapy after 1 week.
  • The average free tissue flap size was 94.3 cm(2) (range, 45-165 cm(2)).
  • Average harvest and ischemia times were 59 minutes (range, 41-87 min) and 187.7 minutes (range, 120-240 min), respectively.
  • CONCLUSIONS: Our results suggest that free tissue transfer reconstruction of the hypopharynx is the preferred method of reconstruction following combined chemotherapy and radiation therapy protocols.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharynx / surgery. Laryngeal Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Wound Healing
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Laryngectomy. Length of Stay. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568540.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Sanabria A, Domenge C, D'cruz A, Kowalski LP: Organ preservation protocols in developing countries. Curr Opin Otolaryngol Head Neck Surg; 2010 Apr;18(2):83-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Conservative surgical procedures, radiotherapy and chemoradiotherapy can all be considered in organ preservation strategies for patients with head and neck squamous cell carcinoma.
  • RECENT FINDINGS: The results of most organ preservation studies are focused on survival and larynx preservation, but an evaluation of quality of life and function of the organ is still lacking.
  • In the present review we consider the possible problems associated with the application of organ preservation strategies in developing countries in some critical areas: advanced stage, comorbidities, nutritional status, long distance to travel, availability of chemotherapy and radiotherapy facilities, tolerance, adherence to protocol standards and expertize in performing salvage surgery.
  • Recent publications strongly suggest that chemoradiation should not be indicated in all patients with advanced laryngeal and hypopharyngeal cancer, but that an individualized treatment strategy should be recommended.
  • SUMMARY: Organ preservation treatments depend on factors related to the physician and the institutions providing healthcare, and also on patients and health systems and socioeconomic factors that make it impossible to extrapolate these results.
  • [MeSH-major] Clinical Protocols / standards. Developing Countries. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Salvage Therapy / standards. Salvage Therapy / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216217.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


98. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging]. Strahlenther Onkol; 2007 Mar;183(3):138-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging.
  • PATIENTS AND METHODS: 600 patients (526 men, 76 women, median age 56 years) with ENT tumors (squamous cell carcinoma histology) were studied retrospectively.
  • The distribution of primary tumor site and stage (AJCC) was as follows: oropharynx: n = 161 (26.8%), hypopharynx: n = 187 (31.2%), oral cavity: n = 89 (14.8%), larynx: n = 118 (19.7%), cancer of unknown origin: n = 13 (2.2%), others: n = 32(5.3%), I: n = 24 (4%), II: n = 49 (8.2%), III: n = 89 (14.8%), IV: n = 438 (73%).
  • The following parameters were analyzed in association with distant metastases: tumor localization, T- and N-category, primary treatment, local tumor control, and second neoplasms.
  • RESULTS: 114/600 patients (19%) developed distant metastases, 29/600 (4.9%) at presentation, 50% within 9.3 months after diagnosis of the primary tumor.
  • Distant metastases were most frequent in stage IV (24.2%), carcinoma of the hypopharynx (25.7%), local recurrence (24.3%), and second neoplasm (31.7%) with the following distribution pattern: pulmonary 61/114 (53.5%), pleural 15/114 (13.1%), osseous 45/114 (39.5%), hepatic 14/114 (12.3%), cerebral 8/114 (7%), cutaneous 14/114 (12.3%).
  • CONCLUSION: With locally advanced ENT tumor stage IVa/b, carcinoma of the hypopharynx, local recurrence or second neoplasms, at least a pretherapeutic CT of the thorax should be performed because every seventh patient (88/600) developed metastases or second primary tumors within the thoracic space during the course of disease.
  • Regarding the side effects and costs of curative therapy, the definition of generally accepted guidelines for the systemic staging of locally advanced ENT tumors should be undertaken.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Otorhinolaryngologic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Bronchogenic / pathology. Carcinoma, Bronchogenic / secondary. Combined Modality Therapy. Disease Progression. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / pathology. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340072.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Yu F, Dong YL, Zu ZJ, Zhan XD, Shu JH, Yang JS, Han GS, Lu LC, Zhang K, Sun HJ, Ren KJ: [Surgical management of hypopharyngeal cancer]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Aug;38(4):295-9
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the preservation of laryngeal function for the patients with hypopharyngeal cancer.
  • Radiotherapy (37 cases), operation only (56 cases) and the combined treatment (operation plus radiation or chemotherapy, 200 cases) were adopted.
  • RESULTS: The 5 year survival rates of patient with laryngeal function preserved and no laryngeal function preserved were 51.3%, 47.6% (for stage III); 40.4%, 43.3% (for stage IV), respectively.
  • The analysis of survival rates revealed a significant difference between combined therapy and radiotherapy.
  • Conservation laryngectomy improves the quality of patient's life, and combined therapy is the best choice for hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Larynx / physiopathology. Larynx / surgery. Male. Middle Aged. Quality of Life. Reconstructive Surgical Procedures. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743643.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


100. van den Broek GB, Rasch CR, Pameijer FA, Peter E, van den Brekel MW, Tan IB, Schornagel JH, de Bois JA, Zijp LJ, Balm AJ: Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer; 2004 Oct 15;101(8):1809-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
  • BACKGROUND: Concurrent chemoradiation is being used increasingly to treat patients with advanced-stage head and neck carcinoma.
  • In the current study, a clinical nomogram was developed to predict local control and overall survival rates for individual patients who will undergo chemoradiation.
  • METHODS: Ninety-two consecutive patients with UICC TNM Stage III/IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and supraglottic larynx were treated with selective-targeted chemoradiation (acronym: RADPLAT).
  • Using tumor volume as a continuous variable, an adjusted risk ratio of 1.026 was found, indicating that each 1-cm(3) increase in volume was associated with a 2.6% decrease in probability of local control.
  • CONCLUSIONS: Tumor volume was found to play a significant role in predicting local control and overall survival in patients with advanced-stage head and neck carcinoma who were treated with targeted chemoradiation.
  • The nomograms may be useful for pretreatment selection of patients with advanced-stage head and neck carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Lymph Nodes / pathology. Male. Middle Aged. Models, Biological. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Probability. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386309.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down






Advertisement